March 2026
Longevity research from March 2026, curated and analyzed through the EDGE Framework.
Can medicine outrun aging? Gerontologist says odds are improving
Longevity escape velocity (LEV) describes the point at which medical interventions extend life faster than aging progresses, requiring a repair-based approach to cellular and molecular damage rather than slowing decline alone. De Grey argues that demonstrating rejuvenation success in animal models will shift scientific consensus and accelerate translation to human therapies.
Longevity biotech investment 2026: we’re set for a breakout year
Longevity biotech financing reached $3.74 billion in Q1 2026 across 49 deals, representing a 56% increase over Q1 2025. Projections for full-year 2026 range from $8.9 billion (mid-range) to $15 billion (aggressive), positioning the sector for sustained capital deployment that could exceed the 2021 peak.
AI-built intrabodies target Alzheimer’s within
Researchers used AI to redesign antibody fragments that can function inside human cells, targeting misfolded proteins linked to Alzheimer's, Parkinson's, Huntington's, and motor neurone disease. This intracellular delivery approach addresses a fundamental limitation of conventional antibodies, which cannot access disease-driving proteins within neurons.
Subtle antiaging injectables become Allergan’s next bet
Allergan Aesthetics is repositioning injectable fillers around 'undetectable' results rather than dramatic transformation, reflecting a measurable shift in consumer preference toward subtle, personalized intervention that respects rather than erases the aging process. This represents a maturation of the aesthetic market toward maintenance-based, individualized support aligned with longevity medicine principles.
Diabetes eye damage linked to higher dementia risk
Type 2 diabetes with worsening diabetic retinopathy correlates with significantly elevated dementia risk, with severe eye disease conferring 58% higher risk for any dementia and more than double the risk for vascular dementia. The retina serves as a measurable window into microvascular integrity throughout the body, including the cerebral vasculature, making routine eye screening a potential early intervention point for cognitive decline.
Modified Immune Cells Target Cancer’s Metabolic Signature
Researchers enhanced natural killer and T cells by engineering them to sense metabolic byproducts produced by tumors, enabling these immune cells to penetrate solid tumors more effectively and improve survival in mouse cancer models. This addresses a fundamental barrier in cancer immunotherapy: the difficulty of getting immune cells to infiltrate the hostile microenvironment surrounding tumors.
Alterity receives positive FDA feedback on ATH434 Phase 3 program
Alterity Therapeutics received FDA feedback supporting its Phase 3 development plan for ATH434, a candidate for Multiple System Atrophy that showed clinically meaningful efficacy in Phase 2 trials. Progression toward Phase 3 testing represents advancement in addressing a neurodegenerative condition with limited therapeutic options.
A Cluster of Three snoRNAs Including Jouvence Required in the Gut Determines Lifespan and Confers Neuroprotection Through Metabolic Parameters
A cluster of three small nucleolar RNAs in the gut epithelium regulates lipid and sterol metabolism, with direct effects on lifespan and neuroprotection in aging. Disruption of these snoRNAs causes metabolic dysregulation that leads to neurodegeneration, while restoration in gut cells alone is sufficient to reverse these effects.
Targeting Mitochondrial Stress Responses: Terbinafine and Miglustat as Novel Lifespan and Healthspan Modulators
Terbinafine and miglustat, FDA-approved drugs, extend lifespan and healthspan by inducing mitochondrial stress responses through coordinated activation of ATFS-1 and DAF-16 pathways. This mechanism represents a distinct integration of mitochondrial and insulin signaling stress responses relevant to aging intervention.
Subcellular orchestration of microglial aging
Microglia—brain immune cells—reorganize their internal structure with age in ways that correlate with functional decline. Subcellular transcript localization patterns reveal how these cells alter their morphology during aging, providing a cellular mechanism underlying age-related cognitive and neurological changes.
Cellular and spatial remodeling of aging breast tissue revealed
Imaging mass cytometry analysis of breast tissue from 527 women reveals that aging is accompanied by decreased cellular density and proliferation, concurrent with increased proportions of inflammatory immune cells. These findings establish a cellular and spatial signature of breast aging that reflects broader patterns of tissue remodeling seen across the body.
Single-cell spatial atlas of the aging human breast
Single-cell imaging of over 500 breast tissue samples reveals that aging is characterized by nonlinear loss of cellular density and a shift toward inflammatory composition. This finding identifies a specific tissue-level signature of aging that may serve as a marker for understanding how systemic aging progresses and potentially how to intervene.
Multiomic single-cell perturbation screens reveal critical lncRNA regulators of senescence
A systematic screen of 32 aging-associated long non-coding RNAs identified HOTAIRM1 as a critical regulator of DNA repair pathways, with restoration of HOTAIRM1 in aged mouse lungs reducing fibrosis. This work establishes lncRNA regulation as a targetable mechanism in cellular senescence.
Thinking in trade-offs: a necessary antidote to diet tribalism
All dietary approaches involve trade-offs rather than universal superiority. Sustainable adherence to a diet that aligns with individual biology and values matters more than the diet's theoretical optimality.
The Longevity Show 80% sold out as inaugural gathers pace
The inaugural Longevity Show has reached 80% capacity in its partner floor with weeks remaining, signaling that longevity has transitioned from niche to mainstream market category. The event's broad ecosystem—spanning diagnostics, nutrition, fitness, therapeutics, and recovery—reflects how health optimization is increasingly understood as systemic rather than vertical.
Private clinics face longevity learning curve
Private longevity clinics are transitioning from theoretical frameworks to clinical practice, but without standardized pathways, creating variability in how preventive interventions are delivered. The challenge now centers on establishing clinical rigor—distinguishing measurable biomarkers from clinically meaningful outcomes—while building scalable, evidence-led models that can eventually extend beyond premium markets.
PREMAZ expands early brain screening through Health is One
PREMAZ, a digital cognitive assessment tool, has partnered with Health is One to integrate early brain screening into everyday wellness services rather than clinical settings. The platform measures memory precision—the sharpness and reliability of recall—to detect subtle cognitive changes before decline becomes clinically apparent, shifting brain health assessment from reactive to preventive.
How a Growth Factor and SIRT1 Might Combat Disc Degeneration
FGF21, a growth factor that declines with age, delays intervertebral disc degeneration by upregulating SIRT1 and restoring mitochondrial quality control through the PINK1-Parkin mitophagy pathway. This mechanism addresses a primary driver of age-related lower back pain by counteracting cellular senescence in disc tissue.
Global rallies call for aging to be treated
Coordinated global demonstrations are pressuring governments to fund geroscience research and establish regulatory pathways that recognize aging as a treatable medical condition. The rallies highlight a critical gap between accelerating scientific advances in longevity research and stalled policy frameworks that remain anchored to disease-specific treatment models.
Lilly races to become first longevity Big Pharma
Eli Lilly's $2.75 billion partnership with Insilico Medicine represents a strategic pivot toward AI-driven drug discovery aimed at aging-related pathology beyond current GLP-1 applications. The deal signals that large pharmaceutical companies now view longevity therapeutics as a commercially serious category worthy of substantial investment in discovery infrastructure.
Pck1 Deficiency Drives Mitochondrial Dysfunction and Cellular Senescence in Adipocytes
Pck1 deficiency in adipocytes impairs mitochondrial function, causing fumarate accumulation that triggers oxidative stress, mtDNA release, and chronic inflammation—a mechanism linking metabolic dysfunction to aging. This identifies a targetable pathway in the progression of age-related metabolic disease.
Allergan Aesthetics highlights undetectable era for HA injectables
Allergan Aesthetics positions hyaluronic acid injectables toward imperceptible aesthetic outcomes through personalized treatment protocols and practitioner training. This reflects a market shift away from obvious augmentation toward integrated facial harmonization strategies.
Insilico, Tenacia expand AI-driven CNS collaboration
Insilico Medicine and Tenacia Biotechnology are expanding their AI-driven collaboration to design small-molecule therapies for central nervous system disorders, with a focus on blood-brain barrier penetration. This partnership demonstrates how generative AI can accelerate drug discovery for neurological conditions, including a candidate targeting NLRP3 inflammation that has cleared FDA review for Parkinson's disease trials.
New AI research reshapes neuroprotective drug discovery funding
Artificial intelligence is accelerating neuroprotective drug discovery across target identification, molecular design, and clinical optimization, with hundreds of millions in venture funding flowing into AI-driven neuroscience companies and major pharma investing in AI-enabled development platforms. This shift compresses timelines for bringing neuroprotective agents to market and expands the addressable therapeutic space for neurodegeneration.
Scalable biotech manufacturing targets $14B cell therapy market
Cell therapy manufacturing capacity is becoming a critical bottleneck as the market expands toward $14 billion by 2035. A joint venture between Avaí Bio and Austrianova is scaling production of genetically modified cells engineered to elevate circulating alpha-Klotho, a protein associated with cellular resilience and healthspan.
Autophagy‐Independent Function of ATG‐18 Is Essential for Gonadal Longevity in Caenorhabditis elegans
ATG-18, a protein long associated with autophagy, extends lifespan through a mechanism independent of autophagy itself when the germline is removed. In the intestine, ATG-18 extends lifespan by interacting with PCK-2, an enzyme involved in glucose production, revealing a tissue-specific, non-autophagic pathway to longevity.
Protect the eyes, protect the brain—a potentially simple lever for dementia risk
Uncorrected cataracts appear associated with elevated dementia risk, and cataract surgery may reduce that risk. This relationship suggests that preserving visual input and the neural processing it supports plays a measurable role in cognitive preservation.
Partnering to Address Social Determinants of Health: Screening Older Adults Through Healthcare and Aging Services Collaboration
Primary care and aging services collaboration can systematically identify and address social determinants affecting older adults' health outcomes. Integration between healthcare and community resources improves detection and intervention for unmet needs that directly influence aging trajectories.
MicroRNA‐128‐3p Deficiency Alleviates Bone Loss in Age‐Related Osteoporosis via Activation of Canonical Wnt Signaling
MicroRNA-128-3p suppresses bone formation by inhibiting Wnt signaling in osteoblasts; its deletion restores bone-building capacity and prevents age-related bone loss in mice. This identifies a molecular brake on skeletal regeneration that accumulates with aging and represents a tractable therapeutic target.
Rubedo Announces Positive Preliminary Results for RLS-1496
Rubedo's RLS-1496, a GPX4 modulator designed to target senescent cells, met primary safety endpoints in a Phase 1 trial and demonstrated dose-dependent clinical improvements in psoriasis, atopic dermatitis, and photoaged skin within four weeks. The compound showed reduced senescent cell burden, decreased inflammatory markers, and increased collagen expression with no serious adverse events.
Rubedo reports early clinical signal for senotherapeutic drug
Phase 1 data for RLS-1496, a GPX4 modulator, demonstrate safety and dose-dependent target engagement alongside reductions in senescence markers and clinical improvement in inflammatory skin conditions. The drug operates through a dual mechanism: clearing senescent cells via ferroptosis while restoring redox balance in stressed neighboring cells, representing a shift toward cellular recalibration rather than indiscriminate senescent cell clearance.
Higher dose semaglutide gets fast FDA nod amid patent pressure
The FDA approved a higher-dose semaglutide formulation (Wegovy HD, 7.2 mg) in 54 days under expedited review, signaling that metabolic disease now carries national priority status alongside traditionally serious conditions. The approval demonstrates additional weight loss benefit with a comparable safety profile to lower doses, though gastrointestinal side effects remain common and new sensory symptoms warrant ongoing monitoring.
The oldest old become longevity biotech’s new map
Human Longevity, Inc. and LEV Foundation are analyzing blood samples from centenarians and supercentenarians using multi-omic analysis to identify molecular and cellular patterns associated with exceptional longevity. This approach shifts the field from theoretical prediction toward evidence grounded in individuals who demonstrate sustained resilience across the human lifespan.
Cellbricks Therapeutics secures €10 million to advance tissue implants
Cellbricks Therapeutics secured €10 million to advance biofabricated tissue implants toward clinical use, focusing initially on adipose tissue for soft tissue defects and wound healing. The funding supports preclinical validation and manufacturing scale-up for vascularized tissue alternatives to synthetic reconstructive implants.
Why the wellness industry needs a new operating system
The wellness industry operates on infrastructure designed for episodic experiences rather than sustained behavioral change over decades. Longevity now requires systems-based approaches that embed healthy behaviors into everyday environments and social contexts, not temporary interventions delivered in specialized settings.
Maze Therapeutics reports positive phase 2 data for MZE829
MZE829, an APOL1 inhibitor, demonstrated a 35.6% mean reduction in urinary albumin excretion at 12 weeks in APOL1-mediated kidney disease, with substantially larger reductions in focal segmental glomerulosclerosis (61.8%) and non-diabetic AMKD (48.6%). The compound was well tolerated with no serious adverse events, positioning it as a potential therapeutic for progressive kidney disease across multiple etiologies.
Human Longevity, Inc. to study centenarians with LEV Foundation
Human Longevity, Inc. and LEV Foundation are conducting multi-omic analyses of centenarians and supercentenarians to identify molecular biomarkers and pathways associated with exceptional longevity. This research bridges the gap between identifying what distinguishes the longest-lived individuals and developing interventions that could extend healthspan in broader populations.
Rubedo reports positive phase 1 results for RLS-1496
Rubedo's RLS-1496, a topical GPX4 modulator, demonstrated dose-dependent efficacy in Phase 1 trials across psoriasis, atopic dermatitis, and photoaged skin, with selective engagement of senescent cells and no serious adverse events. The compound shows potential to restore tissue homeostasis by targeting pathological cellular senescence, a recognized driver of age-related skin conditions and systemic aging.
Immutrin bags $87m for heart amyloid therapy
Immutrin raised $87 million to advance an antibody therapy designed to clear amyloid protein deposits already accumulated in heart tissue, addressing a clinical gap where current treatments only slow production of new deposits. This represents a shift in amyloidosis treatment from disease suppression toward active reversal of established organ damage.
SEMCAP expands into beauty’s longevity opportunity
SEMCAP's expansion into beauty and wellness investment signals a structural shift in longevity markets: evidence-backed skincare, haircare, and personalized health products are becoming primary entry points for consumer engagement with aging well, driven by daily rituals and observable body signals rather than clinical diagnostics alone.
Mitochondria Delivery Method Rescues Parkinson’s in Mice
Researchers encapsulated healthy mitochondria in red blood cell membranes to deliver them into diseased cells, achieving efficient uptake and functional restoration across multiple cellular models of mitochondrial dysfunction. This addresses a long-standing barrier in mitochondrial replacement therapy and demonstrates potential for treating mitochondrial diseases and age-related energy decline.
Staying Together Through Evolving and Personalized Care: Perspectives of Informal Caregivers and Residents on Aging in Place Within a Seniors’ Residence
A model integrating evolving, personalized care within existing seniors' residences supports aging in place by addressing changing assistance needs while maintaining community connection. This approach bridges the gap between independent living and institutional care, reducing fragmentation in service delivery for older adults.
[Articles] Delirium, long-term conditions, and incident dementia in older adults admitted to hospital for emergency care in Lothian, Scotland: a population-based cohort study
Delirium during hospitalization carries a substantial dementia risk in older adults, particularly those without multiple long-term conditions. The association suggests delirium represents either a marker of underlying neurodegeneration or a direct contributor to cognitive decline, warranting systematic assessment protocols in acute care settings.
Senescence‐Driven Remodeling Defines an Aggressive and Immunomodulatory Subtype of Endometriosis
Cellular senescence in ectopic endometrial tissue drives aggressive endometriosis through a PAK4/AKT signaling loop that promotes macrophage-mediated immune remodeling. Stigmasterol, a plant-derived phytosterol, suppresses this pathway and reduces lesion invasiveness in preclinical models, suggesting a mechanism-based therapeutic approach to a senescence-driven disease subtype.
Gut Luminal Exosomes in Young and Old Mice: Multi‐Omic Characteristics and Regulation of Gut Permeability
Exosomes in the gut lumen change composition with age, with those from older mice directly impairing barrier integrity and insulin sensitivity in younger recipients, while young exosomes reverse these effects in older mice. This identifies a specific molecular mechanism linking intestinal barrier dysfunction to metabolic aging.
Dual gene therapy targets muscle aging
Unlimited Bio has initiated a Phase 1/2a clinical trial combining AAV9-Follistatin and VEGF plasmid gene therapy to address age-related muscle loss and vascular insufficiency. The dual approach targets both muscle growth capacity and the circulatory support system that sustains muscle function—a systems-level intervention designed to address interconnected aspects of aging.
Research links GLP-1s to osteoporosis and gout risks
GLP-1 medications are associated with a 30% relative increase in osteoporosis risk and modest increases in gout and bone softening, likely driven by rapid weight loss reducing skeletal load and potential nutritional deficiencies. These findings do not negate the drugs' metabolic benefits but require integrated monitoring and support strategies during treatment.
Herbalife to acquire personalized supplements company Bioniq
Herbalife's acquisition of Bioniq signals market maturation toward data-driven, individually tailored supplementation based on blood biomarkers and lifestyle data. This shift reflects growing recognition that generic micronutrient approaches fail to address individual metabolic variation and optimization needs.
Cellular Senescence and Senotherapeutics: The Expert Roundup
Cellular senescence—the accumulation of cells that cease dividing but resist death—has emerged as a primary target in longevity medicine due to evidence that clearing these cells extends healthspan and can address root causes of age-related disease. Senotherapeutics, including senolytics and senomorphics, are transitioning from preclinical studies to clinical trials, though significant challenges in biomarker standardization, cellular heterogeneity, and clinical efficacy remain.
20/20 BioLabs secures exclusive US license for CKD prediction
20/20 BioLabs has licensed ROKIT Healthcare's chronic kidney disease prediction algorithm to integrate into its OneTest for Longevity platform, which measures inflammatory biomarkers as indicators of biological resilience. CKD affects over 35 million Americans, and early identification through biomarker profiling enables earlier intervention and risk stratification.
EU updates review of blarcamesine from Anavex
Anavex withdrew its EU marketing application for blarcamesine, a candidate Alzheimer's treatment, after the European Medicines Agency signaled it would not recommend approval. The company will gather additional data to address regulatory concerns before resubmission.
Cognito and Ochsner launch brain health collaboratory
Cognito Therapeutics and Ochsner Health have established a regional platform to evaluate Spectris, a non-invasive device that uses synchronized light and sound to stimulate gamma-frequency brain activity, alongside clinical infrastructure to assess its effectiveness in cognitive decline and Alzheimer's disease. The collaboratory will generate real-world data on treatment response, cost-effectiveness, and scalability across diverse populations.
SpectraCell launches Baseline Nexus longevity and risk test
SpectraCell introduced Baseline Nexus, a comprehensive assessment measuring intracellular micronutrient status, lipoprotein profiles, telomere length, and genetic variants through metabolically active lymphocytes rather than serum analytes alone. The test targets early detection of functional cellular deficits that compromise immune function and metabolic capacity—both determinants of health trajectory and aging rate.
GARM expands gene therapy platform with Klotho
GARM Clinic has added Klotho to its non-permanent gene therapy platform alongside Follistatin and VEGF, positioning itself as a clinical destination for early-stage longevity interventions. Klotho addresses age-related decline in the protein's natural production, targeting mitochondrial function, metabolic resilience, and systemic health markers that degrade with age.
Pulmatrix and Eos merge to advance gerotherapeutics
Pulmatrix and Eos SENOLYTIX are merging to develop PTC-2105, a candidate designed to modulate mitochondrial function and clear senescent cells in sarcopenia and metabolic disease. The transaction signals a fundamental shift in biopharma toward targeting aging biology directly rather than its downstream manifestations.
[Editorial] The importance of safeguarding hydration for healthy ageing
Adequate hydration is a critical but often overlooked factor in healthy aging. Dehydration impairs multiple physiological systems and accelerates age-related decline, making hydration status a measurable and modifiable component of longevity strategy.
[Comment] From blueprint to budget: health economics as the compass for China’s National Dementia Action Plan
China's National Dementia Action Plan (2024–30) represents a significant policy commitment to address neurodegenerative disease at scale, yet implementation gaps remain between clinical strategy and resource allocation. Economic evidence and fiscal discipline will determine whether the plan translates intention into measurable health outcomes.
Differential Gene Expression in Human Hippocampus With Aging
Gene expression analysis of human hippocampal tissue reveals distinct molecular signatures in aging characterized by increased inflammation, reduced DNA repair capacity (particularly RAD23B), and altered neural activity patterns. RAD23B expression declines with age and is further reduced in Alzheimer's disease, positioning it as a relevant marker of hippocampal aging and neuronal vulnerability.
Perceived Work Stressors and Job Performance of Employees in Long-Term Care Settings Within the Context of Self-Supporting Care: The Moderating Effect of Perceived Care Recipients Empowerment
Work stress in long-term care settings reduces job performance, but this negative effect is substantially buffered when caregivers perceive the care recipients as empowered and autonomous. Understanding this moderating effect has direct implications for retention, quality of care, and the wellbeing of both caregivers and aging populations.
Developing a Genetic Algorithm-Based Frailty Index for China Health and Retirement Longitudinal Study
Researchers developed a genetic algorithm-based frailty index using nine years of longitudinal data from the China Health and Retirement Longitudinal Study to predict mortality and falls risk in aging adults. This computational approach identifies which physiological and functional markers most reliably indicate vulnerability to adverse outcomes, providing a data-driven alternative to subjective clinical assessment.
Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy
Cognito Therapeutics and Ochsner Health are partnering to test Spectris, a non-invasive neuromodulation device that delivers synchronized light and sound stimulation to restore gamma oscillations disrupted in Alzheimer's disease. Early evidence shows the approach slows cognitive decline and reduces brain volume loss, with the collaboration designed to evaluate real-world clinical implementation across diverse healthcare settings.
The hidden bottleneck in longevity biotech
Longevity biotech's bottleneck lies not in laboratory science but in financial infrastructure—fragmented systems and delayed data visibility cause promising therapies to be shelved despite scientific merit. Unified financial platforms that integrate clinical, operational, and budgetary data in real time can accelerate therapeutic development by improving allocation decisions and reducing administrative friction.
Autophagy angle sharpens Anavex’s investment case for Alzheimer’s
Research published in PNAS Nexus proposes that autophagy dysfunction—a slowdown in cellular recycling—precedes amyloid and tau pathology in Alzheimer's disease. This upstream mechanism shifts the therapeutic target from clearing late-stage debris to restoring the cell's natural cleanup capacity earlier in disease progression.
Parallel Health’s skin microbiome tool aims at precision aging care
Parallel Health's Metabolic Microbiome Profiling measures what skin microbes actively produce—vitamins, antioxidants, fatty acids, and lipids—rather than merely identifying which organisms are present. This functional approach to skin microbiome analysis enables precision interventions tied to barrier function, immune support, and resilience, positioning the skin microbiome as a measurable diagnostic rather than a marketing concept.
Stem cell review targets diabetic wound healing
A systematic review and meta-analysis of allogeneic mesenchymal stromal cell therapies for diabetic foot ulcers found higher rates of complete wound closure and greater reductions in wound size compared to standard care, with no clear signal of serious treatment-related adverse events. The work demonstrates that regenerative cell therapies may support the body's repair capacity when conventional approaches alone prove insufficient in metabolic disease.
Two Polyunsaturated Lipids Demonstrate Senolytic Activity
Two conjugated polyunsaturated fatty acids, α-eleostearic acid and its methyl ester, demonstrated senolytic activity in cell cultures and mouse models across multiple tissues without systemic toxicity. The structural features of these compounds—particularly conjugation patterns and double-bond configuration—correlate with their ability to eliminate senescent cells, which accumulate with age and drive inflammatory cascades linked to chronic disease.
Celosia Therapeutics begins Phase 1b trial of CTx1000 for ALS
Celosia Therapeutics has initiated a Phase 1b trial of CTx1000, a genetic medicine targeting pathological TDP-43 protein in amyotrophic lateral sclerosis. Preclinical data demonstrated halted disease progression and partial reversal of manifestations in ALS models, positioning this as a mechanistic approach to a previously intractable neurodegenerative condition.
C2N highlights first use of eMTBR-tau243 in Evoke phase 3 data
C2N Diagnostics demonstrated that eMTBR-tau243, a plasma biomarker assay, independently predicts cognitive and functional decline in early symptomatic Alzheimer's disease and provides complementary information when paired with p-tau217. This dual-biomarker approach advances the ability to identify patients at higher risk of rapid progression, supporting development of precision medicine strategies for neurodegeneration.
Nanoscope Therapeutics publishes study on functional vision assessment
Nanoscope Therapeutics published validation of the Multi-luminance Shape Discrimination Test as a functional vision measure in severe retinal disease, with their lead therapy MCO-010 demonstrating clinically meaningful vision improvements in retinitis pigmentosa patients. This represents progress toward the first FDA-approved treatment for vision restoration in advanced retinal degeneration.
Annovis partners with NeuroRPM on Parkinson’s study
Annovis is combining continuous movement monitoring via FDA-cleared AI with skin-based alpha-synuclein biomarkers to measure treatment response in a 36-month Parkinson's trial. This dual approach—capturing real-time motor dysfunction alongside objective pathological markers—establishes measurable endpoints for evaluating buntanetap's disease-modifying potential.
Alnylam advances ATTR-CM detection with Viz.ai and AHA support
Alnylam is implementing AI-enabled diagnostic pathways and clinical learning collaboratives to accelerate detection of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a progressive cardiac condition often diagnosed late. Earlier detection of this condition directly impacts treatment outcomes and disease trajectory, making systematic screening improvements clinically significant.
The Mediating Effect of Self-Transcendence on the Correlation Between Frailty and Life Satisfaction in the Elderly
Self-transcendence—the ability to look beyond oneself toward meaning, purpose, and connection—significantly buffers the relationship between physical frailty and life satisfaction in older adults. This psychological mechanism explains why some frail individuals maintain high subjective well-being despite objective physical decline.
Senescence‐Driven IL‐17A Inflammatory Circuit Promotes Epithelial–Mesenchymal Transition (EMT) and Progression in Age‐Related Posterior Subcapsular Cataracts
Senescent lens epithelial cells drive posterior subcapsular cataracts through an IL-17A inflammatory loop that activates NF-κB signaling, triggering epithelial-mesenchymal transition and accelerated tissue remodeling. This positions age-related cataracts as a senescence-driven pathology rather than a protein aggregation problem, with implications for understanding how cellular aging propagates through tissues.
Protein intake and its interaction with dietary patterns on clinical outcomes among older adults
Protein intake's effects on clinical outcomes in older adults depend significantly on overall dietary pattern, not protein amount alone. This interaction demonstrates that isolated nutrient optimization without attention to dietary context produces limited or inconsistent health benefits.
NOVOS trial explores vascular aging markers
A randomized, double-blind, placebo-controlled trial in 43 healthy adults over 40 found that a multi-component nutritional intervention improved endothelial function by 2.9%, reduced arterial stiffness by 1.18 m/s, and lowered systolic blood pressure by 6.1 mmHg over six months. These improvements in vascular function markers suggest the intervention may address structural and functional aging of the arterial system, with effect sizes comparable to or exceeding those from exercise interventions.
Biophytis-LynxKite AI alliance broadens longevity drug pipeline
Biophytis and LynxKite are expanding their AI-driven drug discovery partnership beyond sarcopenia to build a broader platform for age-related diseases, including dry age-related macular degeneration. The alliance demonstrates a concrete application of AI to accelerate candidate identification and reduce development timelines in longevity therapeutics.
Perplexity enters the consumer health AI arena
Perplexity has launched an AI-powered health platform that aggregates fragmented health data from medical records, wearables, and provider systems into a unified dashboard, enabling personalized health insights grounded in individual biomarkers and trends. This addresses a critical infrastructure gap in longevity practice: the ability to contextualize health signals across time and across systems, moving beyond isolated data points toward pattern recognition that supports earlier intervention.
Galimedix touts lower-dose oral Alzheimer’s drug
Galimedix presented preclinical data on a prodrug formulation of its oral Alzheimer's candidate that achieves higher systemic drug exposure at lower doses by improving absorption efficiency. The advancement addresses a critical practical constraint in neurodegenerative disease treatment: long-term medication adherence and tolerability.
Basecamp Research’s new gene atlas could speed longevity R&D
Basecamp Research's Trillion Gene Atlas expands genetic reference data 100-fold across 100 million species to improve AI drug discovery models for aging. The underlying premise is that current AI systems underperform not due to model limitations but because they train on narrow, repetitive biological data insufficient for solving complex, multisystem conditions like aging.
BioAge Labs Provides Business Updates
BioAge Labs reported positive interim Phase 1 data for BGE-102, an oral NLRP3 inhibitor, demonstrating significant reductions in inflammatory cardiovascular biomarkers (hsCRP 86%, IL-6 58%, fibrinogen 30%) and brain penetration. The company is advancing toward Phase 2a trials in cardiovascular disease and expanding into ophthalmology for diabetic macular edema, positioning the compound as a multi-indication anti-inflammatory therapy.
In Vivo Created CAR T Cells Eliminate Tumors in Mice
Researchers used CRISPR-based delivery vehicles to generate CAR T cells directly within living mice, achieving complete tumor elimination in leukemia models without the 3-5 week ex vivo manufacturing process. This in vivo approach demonstrates higher efficacy than conventional methods and addresses critical barriers to CAR T accessibility and speed.
Role of Succinate Dehydrogenase in Age‐Related Th17 Inflammation
Succinate dehydrogenase (SDH), a mitochondrial enzyme, becomes overactive in aging T cells and drives an age-related shift toward Th17 inflammatory responses. Inhibiting SDH in older adults' T cells reduces proinflammatory cytokine production, while restoring succinate levels in younger T cells reproduces the inflammatory profile seen in aging.
Blarcamesine links functional and cognitive outcomes in AD-004 trial
Blarcamesine demonstrated a measurable correlation between MRI-detected preservation of brain volume and slowing of cognitive decline in early Alzheimer's disease, with particularly strong outcomes in a genetically defined subpopulation. Long-term data suggest a potential delay in functional deterioration of approximately 18 months over 33 months of treatment.
[Corrections] Correction to Lancet Healthy Longevity 2025; 6: 100749
A correction to a randomized controlled trial comparing Iyengar yoga-based exercise to seated relaxation for fall prevention in adults over 60. The original study demonstrated that structured, alignment-focused movement practice reduced fall incidence more effectively than passive relaxation approaches in this population.
Buck Institute Launches Healthspan Horizons
The Buck Institute launched Healthspan Horizons, a research infrastructure platform that integrates longitudinal multi-modal health data from wearables, activity, nutrition, and labs to identify patterns driving healthy aging and detect early disease signals. This addresses the critical gap between lifespan extension and healthspan maintenance—the years lived in functional health rather than chronic disease management.
Neuroscience of Vitality and Aging Conference in Boston
The Neuroscience of Vitality and Aging Conference brings together researchers, clinicians, policymakers, and investors to address brain health preservation and neurodegenerative disease prevention. The event recognizes brain aging as a modifiable biological process and aims to translate fragmented research across academia, industry, and policy into coordinated clinical advancement.
NeuroRPM to provide AI monitoring for Annovis Parkinson’s trial
NeuroRPM's FDA-cleared wearable platform will continuously monitor motor symptoms in a 500-participant Parkinson's disease trial, using Apple Watch data to measure bradykinesia, tremor, and dyskinesia with algorithmic precision. This represents the first FDA-cleared AI device for real-world Parkinson's symptom tracking, enabling detection of treatment response at granularity not achievable through standard clinical assessments alone.
ProMIS Neurosciences details new ALS and Parkinson’s data
ProMIS Neurosciences presented preclinical vaccine data targeting misfolded proteins in ALS, Parkinson's, and Alzheimer's disease. The approach uses computational epitope selection to generate selective immune responses against pathogenic protein conformations implicated in neurodegeneration.
Unlimited Bio registers dual gene therapy trial
Unlimited Bio initiated a Phase 1/2a trial combining AAV9-Follistatin and VEGF plasmid gene therapies to address age-related muscle decline, marking the first registered clinical study to combine these two approaches. The dual-therapy strategy targets both muscle growth signaling and vascular support, with safety and functional outcomes tracked over 12 months in adults aged 45 to 75.
Fauna Bio reaches target designation in Lilly obesity collaboration
Fauna Bio identified a novel obesity treatment target through comparative analysis of hibernating mammal biology integrated with human genomic data, using AI-driven target prioritization. This represents a shift toward leveraging natural metabolic strategies—particularly those evolved for extreme energy conservation—as a foundation for therapeutic development in metabolic disease.
Garm adds Klotho to cell and gene therapy platform in Roatan
Garm LLC expanded its non-permanent plasmid gene therapy platform to include Klotho alongside existing follistatin and VEGF therapies, targeting mitochondrial function, inflammation reduction, oxidative stress management, and metabolic aging. The platform operates in Roatan, Honduras, positioning itself as a personalized longevity intervention without permanent genetic modification.
When Doctors Prescribe Horoscopes: The Trouble With Biological Age Tests
Commercially available biological age tests based on epigenetic markers lack clinical validity, standardized accuracy measures, and actionable clinical utility. When physicians recommend them, they abandon evidence-based practice in favor of customer satisfaction, potentially replacing genuine health assessment with unfounded reassurance or unnecessary anxiety.
RevGenetics unveils absorption-gap solution for berberine
RevGenetics has developed DiBerberine 300x, an enteric-coated supplement combining dihydroberberine with a proprietary flavonoid complex designed to overcome two primary absorption barriers: stomach acid degradation and P-glycoprotein efflux. The formulation reportedly achieves 6.7-fold greater plasma exposure compared to standard berberine at lower doses, addressing a long-standing bioavailability limitation that has constrained berberine's clinical utility.
New findings link autophagy failure to early Alzheimer’s pathology
Impaired neuronal autophagy precedes amyloid-beta and tau pathology in Alzheimer's disease, suggesting that restoring cellular clearance mechanisms may address disease onset at a mechanistic level upstream of classical biomarkers. This positions autophagy dysfunction as a tractable target for intervention before irreversible neurodegeneration.
Elitra Health launches concierge primary care program
Elitra Health launched a concierge primary care program limiting physician panels to 35 patients and offering 24/7 access, same-day appointments, and integrated preventive care coordination. The model prioritizes continuity of care and early detection through advanced diagnostics and personalized wellness planning as an alternative to volume-based primary care.
Stop treating women as an exception in aging science
Aging science built primarily on male biology has systematically misunderstood female physiology, leading to ineffective or harmful optimization strategies for women. A female-centered approach recognizes that women's hormonal cycles are rhythmic rather than erratic, and that sex-based differences in metabolism, hormone production, and social bonding represent distinct biological advantages requiring tailored intervention.
Longevity wake-up call for younger generations
Mortality rates among Gen X and Millennials are rising relative to prior generations, driven by elevated cardiovascular disease, cancer, and external causes rather than medical innovation gaps. This reversal signals that longevity progress depends fundamentally on lifestyle, social determinants, and stress management rather than treatment advances alone.
Senescence consortium targets biomarker gap
The Senotherapeutics Biomarker Consortium addresses a critical gap in senescence measurement standards across academia, industry, and regulators. Standardized biomarkers are essential to advance clinical translation of senotherapeutic interventions, as current measurement heterogeneity impedes trial reproducibility and regulatory confidence.
Gubra-AbbVie obesity drug nears 10% weight loss
ABBV-295, an amylin-mimetic therapy from Gubra and AbbVie, produced 7.75–9.79% weight loss over 12 weeks in Phase 1 trials with a favorable safety profile. The drug targets a distinct hormonal pathway from current GLP-1 therapies, offering potential for multi-signal appetite regulation and sustained metabolic improvement.
Experimental pill cuts ‘bad cholesterol’ by up to 60%
Enlicitide, an oral PCSK9 inhibitor, reduced LDL cholesterol by 57% in phase 3 trials—matching injectable versions' efficacy while improving accessibility. This addresses a significant implementation gap in cardiovascular prevention, where non-adherence to injectable therapies limits population-level risk reduction despite proven biological effectiveness.
Examining the Role of Dementia Worry in the Caregiver Burden Process
Dementia worry among family caregivers intensifies caregiver burden through increased stress and emotional strain, with anxiety about personal cognitive decline amplifying the physiological and psychological toll of caregiving responsibilities. This dynamic represents a critical but often-unmeasured pathway through which caregiver stress translates into health deterioration.
#385 – AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and more
This AMA addresses practical applications of longevity science across disease prevention, body composition assessment, nutritional strategy, movement quality, and habit implementation. The focus is on translating evidence-based tools into sustained clinical and personal practice for extending both lifespan and healthspan.
Trajectories of physical function and biological aging in generally healthy older adults with and without incident invasive cancer over a three-year follow-up: findings from the DO-HEALTH study
Older adults who developed cancer over three years showed accelerated decline in physical function and biological aging markers compared to cancer-free peers, even when starting from similar baseline health. Physical deterioration preceded or accompanied cancer diagnosis, suggesting measurable functional decline tracks with malignant disease progression.
Dietary metabolomic determinants of frailty through inflammation in the Canadian Longitudinal Study on Aging
Specific dietary metabolites—compounds produced when the body processes food—predict frailty risk through inflammatory pathways in aging adults. This identifies measurable intermediate markers that connect diet composition to loss of physical function, a primary driver of morbidity and mortality in older populations.
[Review] Prediction models for overall survival and all-cause mortality risk in older adults with cancer: a systematic review
Existing mortality prediction models for older adults with cancer show substantial bias and inconsistent validation, limiting their clinical reliability. Systematic evaluation of 250 studies reveals that most models lack adequate external validation and transparent reporting of performance metrics, raising questions about their utility in clinical decision-making for this population.
When sophisticated models meet questionable premises
Mendelian randomization, while mathematically sophisticated, produces unreliable conclusions when applied to causal questions for which the underlying biological assumptions are violated. The method's power lies not in the sophistication of its statistical machinery, but in the validity of its foundational premises—a distinction often lost in genomic research.
RNA Recycling Extends Lifespan
RNASEK, an enzyme that degrades circular RNA accumulation in cells, extends lifespan in model organisms by removing a form of molecular waste that accelerates aging. This identifies a specific degradation pathway central to cellular longevity.
Atrogi begins human trial for muscle-preserving weight loss
Atrogi has initiated human trials of ATR-258, an oral drug designed to preserve muscle mass during weight loss by mimicking exercise-induced metabolic effects. The approach addresses a critical gap in current obesity therapeutics: preventing muscle loss alongside fat loss, which is essential for maintaining strength, resilience, and functional independence in aging.
Sequential banks $3.5m for smarter skin health
Sequential, a Cambridge-based skin health testing company, raised $3.5 million to build an AI discovery engine powered by over 50,000 clinical samples and 4,000+ ingredients. The platform measures microbial and host biomarkers to identify which ingredients actually affect skin function—moving personal care from marketing claims to measurable biological outcomes.
AlzeCure presents new preclinical data on NeuroRestore ACD856
ACD856, a first-in-class Trk receptor modulator, demonstrates dose-dependent activation of neurotrophin signaling pathways in preclinical models, with concurrent neuroprotective and antidepressant effects. This mechanism addresses a significant comorbidity pattern in Alzheimer's disease pathology where cognitive decline and mood disturbance are mechanistically linked.
Totus Medicines reports Phase 1a data for TOS-358
TOS-358, a selective mTOR complex 1 inhibitor, demonstrated a 50% clinical benefit rate and 75% disease control rate in Phase 1a testing, with a notably favorable safety profile compared to existing PI3K/AKT/mTOR pathway inhibitors. The compound showed efficacy in patients resistant or intolerant to standard therapies in this class, positioning it as a potential therapeutic option for advanced malignancies.
Aspen Neuroscience reports positive 12‑month ASPIRO results
Aspen Neuroscience's Phase 1/2a trial of sasineprocel (ANPD001), a cell-based therapy for Parkinson's disease, demonstrated safety and functional improvements at 12 months in eight patients, with gains in motor function, quality of life, and reduced medication burden. These results support advancement to Phase 3 evaluation of a regenerative approach to dopaminergic neurodegeneration.
Meat Consumption May Benefit APOE4 Carriers
A 15-year Swedish cohort study found that unprocessed meat consumption was associated with preserved cognitive trajectory and reduced dementia risk in APOE ε4 carriers, effectively neutralizing the genotype's established cognitive penalty at higher intake levels. This finding challenges the assumption that ε4 carriers universally benefit from plant-forward diets and suggests ancestral dietary patterns may interact with genetic risk architecture in ways that modern nutritional guidelines do not account for.
New brain-cell map sharpens ALS therapy hunt
Researchers have mapped five specific neuron subtypes in the motor cortex that are selectively vulnerable to TDP-43 aggregation in ALS and frontotemporal dementia. This cellular-level precision redirects therapeutic strategy from broad protein-removal approaches toward targeted neuroprotection tailored to neuron type.
UK nod for Soligenix drug links rare disease to healthspan
Soligenix's SGX945 has received UK Promising Innovative Medicine designation for Behcet's disease, a rare inflammatory disorder characterized by recurrent immune-mediated flare-ups affecting multiple tissues. This regulatory milestone reflects growing recognition that chronic inflammatory conditions significantly impact healthspan and warrant accelerated development pathways when clinical evidence demonstrates meaningful advantage over existing options.
Age‐Like Methylation Changes of HSCs in GADD45B Knockout Mice Define Methylation Sites Associated With Loss of Function
GADD45B deletion induces DNA methylation patterns resembling age-associated changes in hematopoietic stem cells, yet these methylation alterations occur without functional decline. The research distinguishes between methylation signatures and actual loss of HSC capacity, providing a resource to identify which methylation sites causally drive age-related hematopoietic dysfunction.
FGF21‐Mediated Upregulation of SIRT1 Delays Intervertebral Disc Degeneration by Promoting PINK1/Parkin Dependent Mitophagy Through Deacetylation of FOXO3
FGF21 activates a cellular repair pathway in spinal disc cells by upregulating SIRT1, which deacetylates FOXO3 and triggers mitochondrial autophagy, thereby suppressing cell senescence and slowing intervertebral disc degeneration. This identifies a targetable molecular axis with direct relevance to preventing age-related spinal structural decline and associated disability.
Issue Information
This issue of Aging Cell (Volume 25, Issue 4, April 2026) aggregates current research on cellular and organismal aging mechanisms. Without access to specific article abstracts or contents, the longevity relevance depends on the individual research papers included in this issue.
MODAG brings world’s first Parkinson’s test to market
MODAG has launched PD DETECT, the first CE-certified biochemical test for Parkinson's disease, enabling detection of alpha-synuclein aggregates in cerebrospinal fluid with 97.8% sensitivity and 100% specificity. This shifts diagnosis from clinical observation to objective molecular evidence, potentially enabling earlier intervention before motor symptoms fully manifest.
ImmunoBrain presents Phase 1b data for immune checkpoint therapy
ImmunoBrain's anti-PD-L1 therapy (IBC-Ab002) demonstrated acceptable safety and tolerability in early Alzheimer's patients, with cerebrospinal fluid biomarkers suggesting potential protection against synaptic and neuronal decline. This represents a shift toward immune-based approaches for neurodegenerative disease, targeting the chronic immune suppression that characterizes aging.
ALZpath cements pTau217 as Alzheimer’s diagnosis frontrunner
ALZpath's pTau217 antibody is establishing itself as a standardized infrastructure tool for blood-based Alzheimer's diagnosis, with 29 presentations at AD/PD 2026 demonstrating reproducibility across multiple research settings and clinical developers. The significance lies not in pTau217's promise alone, but in its emerging role as a scalable, platform-agnostic diagnostic that can integrate into routine medical practice rather than remain confined to specialized labs.
Association Between Frequency and Type of Social Participation and Incidence of Frailty Among Non-Frail Japanese Older Adults: Three-Year Prospective Cohort Study
Frequent social participation, particularly in groups and community activities, reduced frailty incidence by 30-40% over three years in non-frail Japanese older adults. The protective effect was strongest for regular (weekly or more) engagement across multiple activity types.
Four-Year Associations Between Cancer Trajectories, Depression and Grip Strength in European Older Adults
In older European adults, cancer diagnosis and persistence over four years associated with increased depression and declining grip strength, with bidirectional relationships suggesting depression may both precede and follow cancer diagnosis. These associations point to measurable physiological markers of systemic decline that warrant monitoring alongside oncological outcomes.
Electrocardiogram derived heart age models agreement, accuracy and predictive ability in the Tromsø study
Electrocardiogram-derived heart age models show moderate agreement with chronological age but demonstrate significant individual variation, with predictive accuracy for cardiovascular outcomes varying substantially depending on the specific model used. This suggests ECG-based age estimates require careful interpretation and cannot yet replace traditional risk assessment tools.
Spontaneous aging-associated inflammation and genome instability in the immune system of turquoise killifish
Turquoise killifish demonstrate rapid, age-associated immune system deterioration marked by chronic inflammation, genomic instability, and functional decline. This model reveals how innate immune dysregulation accelerates aging trajectories in vertebrates, offering mechanistic insights applicable to understanding human immunosenescence.
Mitorubin, berberrubine-based compounds that improve mitochondrial function, exhibit cardioprotective effects against age-related cardiac dysfunction
Mitorubin, a berberrubine-derived compound, restores mitochondrial function and protects cardiac tissue from age-related deterioration. This addresses a primary mechanism of cardiovascular aging by targeting energy production capacity at the cellular level.
Targeting protein misfolding in neurodegeneration
Protein misfolding drives over 100 diseases and accelerates aging-related decline. Origami Therapeutics is developing targeted protein degraders and conformation correctors that address root cause mechanisms rather than symptoms, with initial focus on neurodegenerative diseases including Huntington's, Alzheimer's, and Parkinson's.
R1 launches with $77.5m for chronic kidney disease drug
R1 Therapeutics has secured $77.5 million in Series A funding to advance AP306, a drug candidate that blocks intestinal phosphate absorption in chronic kidney disease patients on dialysis. The approach addresses a decades-old treatment gap where over 40% of dialysis patients fail to achieve phosphate control with existing therapies, largely due to high pill burden and gastrointestinal side effects.
NLRP3: the inflammation master switch – a DLT Chatbot guide
NLRP3 represents a central regulatory hub in innate immunity with therapeutic potential across neuroinflammation, cardiometabolic disease, and ocular conditions. Approximately 50 companies are advancing 66 NLRP3-targeted assets through clinical pipelines, with the highest concentration in CNS and cardiometabolic indications, positioning inflammasome modulation as a significant therapeutic frontier.
SuperAgers reveal a regenerative brain signature
SuperAgers—individuals over 80 with memory performance matching those decades younger—maintain roughly twice the neurogenic capacity of age-matched peers, driven by preserved epigenetic regulation that keeps regenerative neural programs accessible. This finding reframes cognitive aging from inevitable decline to a regulated, potentially modifiable biological process.
Using mRNA to Fight Tau Aggregation in Alzheimer’s
Researchers developed a lipid nanoparticle that delivers mRNA encoding TRIM11, a natural ligase that disaggregates tau tangles, across the blood-brain barrier in mouse models of Alzheimer's disease. Treatment produced sustained cognitive and behavioral restoration comparable to wild-type mice, with reduction in tau pathology and neuroinflammatory markers.
Wisp widens telehealth model with women-centric longevity
Wisp, a women-focused telehealth platform, has launched a longevity category offering NAD+, glutathione, and low-dose naltrexone through clinician-guided care rather than biohacking positioning. The move addresses a significant gap: 75% of women prioritize long-term health, yet only 11% feel current digital tools provide meaningful control over aging outcomes.
ADDF launches new phase of $150m Alzheimer’s diagnostics accelerator
The Alzheimer's Drug Discovery Foundation has committed an additional $50 million to its Diagnostics Accelerator program, now totaling $150 million, to advance blood-based biomarkers, multi-marker panels, and AI-driven diagnostic tools for Alzheimer's disease. This investment targets earlier detection and disease monitoring to enable preventive interventions and combination therapies before irreversible neurodegeneration occurs.
Serina Therapeutics secures up to $30m to advance Parkinson’s program
Serina Therapeutics secured $15 million in immediate funding with up to $15 million additional to advance SER-252, a candidate for Parkinson's disease, through a Phase 1b single-ascending dose registrational study. Topline results are targeted for the first half of 2027, representing progress in a therapeutic approach to a neurodegenerative condition where current options remain limited.
Fauna Bio hits key milestone in Lilly obesity drug collab
Fauna Bio identified a metabolic disease drug target for obesity by studying hibernating ground squirrels, triggering a milestone payment in its partnership with Eli Lilly. The approach leverages comparative genomics across 450+ mammalian species to discover metabolic pathways that address underlying disease mechanisms rather than appetite suppression alone.
Aging Triggers an Intestinal Energy Crisis and HDL3 Deficiency Disrupting Gut–Liver Axis Homeostasis
Aging impairs intestinal mitochondrial energy production, reducing HDL3 synthesis and disrupting the gut-liver axis, allowing inflammatory lipopolysaccharide to damage the liver. NMN restores NAD+ availability, rebuilds HDL3 production, and reverses this age-related hepatic injury in experimental models.
Aging in Place or Institutional Care? Exploring Daily Life Experiences and Attitudes Toward Nursing Home: A Comparative Qualitative Study on Older Adults
Older adults' experiences and perceptions of aging in place versus institutional care settings differ significantly, with implications for quality of life, autonomy, and health outcomes in later years. Understanding these preferences and lived experiences is essential for designing care models that align with individual health trajectories and psychological well-being.
The puzzling duality of mesenchymal stem cells and adipocytes in bone marrow and ageing
Mesenchymal stem cells in bone marrow show contradictory roles in aging—they support bone regeneration but accumulate as fat cells that displace bone-forming capacity. This duality reveals why bone density declines despite maintained stem cell populations, a critical mechanism in skeletal aging.
Plastic bottles make life-saving Parkinson’s drug
University of Edinburgh researchers have engineered E. coli bacteria to convert discarded PET plastic bottles into L-DOPA, a primary treatment for Parkinson's disease motor symptoms. This demonstrates a scalable biotechnology approach that replaces petroleum-based pharmaceutical synthesis with waste-derived production, reducing both environmental burden and potentially manufacturing costs.
Longevity.Technology has quietly become an AI company
Longevity.Technology has transitioned from a media platform into an AI-native data infrastructure company, launching DLT (Decoding Longevity Trends), a three-stage system that aggregates, validates, and surfaces actionable intelligence on longevity and age-related disease biotechs. This infrastructure shift enables precision decision-making for investors, founders, and pharmaceutical development teams across a rapidly fragmenting landscape of aging research.
Longevity public stocks are investable: here’s a DLT Chatbot guide
This article describes a data-driven approach to constructing longevity biotech investment portfolios by mapping public companies to the hallmarks of aging rather than disease labels. The mechanism-first framework enables investors to identify companies with broader pipeline optionality and reduced concentration risk across the fragmented longevity biotech landscape.
Defeating entropy: London takes on Longevity Levels 9 and 10
A London conference examines Longevity Levels 9 and 10—strategies that shift from slowing aging to replacing worn biological structures entirely, including whole brain emulation, organ replacement, and biostasis. These approaches represent a fundamental philosophical and technical departure from maintenance-focused longevity, treating the body as a modular system where critical components can be swapped rather than repaired.
Three drugs in major study to prove their capacity to slow aging
UT Health San Antonio is launching VITAL-H, a $38 million clinical trial enrolling over 700 adults to test whether three existing drugs—rapamycin, semaglutide, and dapagliflozin—can slow biological aging in humans. This represents the first large-scale human trial specifically designed to evaluate pharmaceutical intervention in aging processes.
Negative Interactions Are Associated With Faster Aging
Individuals with more problematic people in their close social networks exhibit accelerated biological aging, with each additional "hassler" associated with a 1.5% faster aging pace and approximately 9.5 months of additional biological age. This effect persists after controlling for demographic, occupational, and health factors, establishing social stress as a measurable driver of epigenetic aging.
ARDD 2026 to relocate to Boston
The Aging Research & Drug Discovery (ARDD) conference, previously held annually in Copenhagen, has been canceled by the University of Copenhagen and will relocate to Boston as part of Boston Longevity Week in October 2026. The relocation reflects shifting geography in longevity research infrastructure and pharmaceutical industry engagement with aging science.
Alchemab Therapeutics names Ulrich Wendt chief business officer
Alchemab Therapeutics appointed Ulrich Wendt as Chief Business Officer to expand partnerships and advance its AI-enabled antibody discovery platform. This represents operational scaling of a company using disease-resilient individuals' immune profiles to identify protective antibodies for difficult-to-treat conditions.
Cellino appoints Ed Tekeian as chief operating officer
Cellino appoints Ed Tekeian as Chief Operating Officer to oversee scaling of autonomous biomanufacturing systems for personalized cell-based regenerative therapies. This leadership move signals the company's readiness to advance from platform development toward clinical-scale production of patient-specific induced pluripotent stem cells.
Cognition Therapeutics reports Zervimesine slows NPI decline in DLB
Zervimesine (CT1812) demonstrated an 86% slowing of neuropsychiatric symptom decline in dementia with Lewy bodies patients compared to placebo in Phase 2 testing. This result supports advancement to late-stage trials and suggests a potential disease-modifying mechanism for a condition with limited therapeutic options.
Anavex reports blarcamesine benefits in Parkinson’s disease model
Blarcamesine, a sigma-1 receptor agonist, demonstrated statistically significant improvements in motor function and reduced alpha-synuclein pathology in a preclinical Parkinson's disease model. The mechanism appears to engage underlying disease processes through modulation of cellular stress responses and protein homeostasis rather than symptomatic relief alone, with implications for disease-modifying approaches in neurodegeneration.
Parallel Health unveils skin microbiome mapping technology
Parallel Health has developed Metabolic Microbiome Profiling, a technology that maps the functional output of skin microbes rather than merely identifying species presence. This approach links microbial metabolite production—including vitamins, antioxidants, and short-chain fatty acids—to skin aging phenotypes, enabling personalized dermatological intervention based on actual biochemical activity rather than microbial composition alone.
Cognito Therapeutics presents Spectris data in Alzheimer’s disease
Cognito Therapeutics presented clinical and biomarker data supporting Spectris, a non-invasive neurostimulation therapy using synchronized light and sound to modulate gamma frequency brain waves in Alzheimer's disease. Prior studies showed preserved brain structure, slowed cognitive decline, and reduced atrophy compared with controls, with favorable safety profiles and no amyloid-related imaging abnormalities.
Atria Health partnership supports expansion of cardiac care network
Atria Health and Stern Cardiovascular have formed a partnership to expand cardiac care access across the Mid-South through a physician-led model that provides capital and operational support without acquiring practices. This arrangement addresses growing demand for cardiovascular services while maintaining physician autonomy and improving care efficiency across three states.
Avoidance of rejuvenation: a stress test for evolutionary theories of aging
Evolutionary theory predicts that organisms should invest in rejuvenation when it is energetically favorable, yet most do not. This paradox reveals fundamental constraints on aging that challenge current models of senescence and suggests the biological capacity for rejuvenation may be far more limited than previously assumed.
Ternary raises $4.4m to fight inflammaging with AI drugs
Ternary Therapeutics raised $4.4 million to develop AI-designed molecular glues that selectively degrade or modulate proteins driving chronic inflammation and neuroinflammation. This approach addresses inflammaging, a fundamental aging process linked to age-related disease burden, through a closed-loop AI platform rather than conventional blocking mechanisms.
Roche gets CE mark for Alzheimer’s risk blood test
Roche has obtained CE mark approval for a blood test that identifies ApoE4 carriers, a genetic variant associated with increased Alzheimer's risk. This test streamlines risk stratification and treatment planning by enabling clinicians to prioritize patients for further evaluation and guide therapeutic decisions, particularly regarding amyloid-targeting therapies that carry differential risk profiles based on ApoE4 status.
Evolve Science launches longevity peptide platform
Evolve Science has launched a peptide and longevity platform that differentiates itself through supply chain transparency and batch-level documentation rather than marketing claims. The company sources products exclusively from FDA-registered US compounding pharmacies and requires Certificates of Analysis for every product, addressing a documented gap in quality verification within the longevity market.
Gyms tap medical longevity with Serotonin Centers’ model
Serotonin Centers is establishing medical longevity suites within existing fitness facilities across the US, integrating diagnostic assessment and clinical interventions (hormone optimization, GLP-1 therapy, peptide protocols, recovery technologies) directly into gyms. This model addresses the recognition that exercise alone is insufficient for sustained health optimization and positions gyms as access points for comprehensive, medically supervised longevity care.
Vail Health makes case for prevention-led longevity
Vail Health's clinical leadership argues that foundational prevention practices—exercise, sleep, strength training, social connection, and purpose—remain the most impactful drivers of longevity, and that advanced diagnostics add value only when they prompt behavioral change. This reframes the longevity conversation away from technology and supplements toward the habits most people neglect.
Study Links a Gut Bacterium to Increased Muscle Strength
Roseburia inulinivorans, a gut bacterium, correlates with 29% higher handgrip strength in older adults and produces a 30% increase in grip strength in mice through mechanisms involving muscle fiber composition and cross-sectional area. This identifies a specific microbial species with causal links to muscular strength independent of body mass or exercise capacity.
The Adiponectin‐PP2A Pathway Confers Cognitive Benefits of Physical Exercise Against Chronic Stress‐Induced Tau Hyperphosphorylation in the Hippocampus
Physical exercise elevates circulating adiponectin, which activates PP2A phosphatase in the hippocampus to reduce pathological tau phosphorylation and restore cognitive function under chronic stress. This mechanism operates independently of adiponectin's other metabolic functions and identifies a direct molecular pathway by which exercise protects against Alzheimer's-like neuropathology.
Early-Life Hunger and Willingness for Institutional Care: Evidence From the China Longitudinal Aging Social Survey
Early-life nutritional deprivation correlates with reduced willingness to accept institutional care in older age, based on longitudinal data from Chinese populations. This finding suggests developmental programming affects not only metabolic health but also decision-making patterns and social preferences decades later.
Annovis reports 2025 results and advances buntanetap trials
Annovis advanced Phase 3 trials of buntanetap, an oral therapy targeting neurotoxic protein production in Alzheimer's and Parkinson's disease, with 65% enrollment completion and biomarker evidence of reduced neurodegeneration markers. The candidate addresses multiple pathological pathways implicated in neurodegeneration, positioning it as a potential disease-modifying intervention rather than symptomatic treatment alone.
Mapping and Measuring Access to Adult Day Services for Persons With Dementia: A One State Illustration
This research maps the availability and accessibility of adult day services for people with dementia across Mississippi, identifying gaps in community-based care infrastructure. The study provides a framework for evaluating whether existing services meet the needs of dementia patients and their caregivers at the state level.
Longitudinal changes in epigenetic clocks predict long-term mortality
Longitudinal changes in epigenetic clocks—molecular markers of biological age—independently predict mortality over 24 years, independent of baseline biological age. This establishes that the rate of epigenetic change itself, not just absolute age status, carries clinically actionable information for longevity assessment.
Hydroxychloroquine alleviates cyclophosphamide-induced premature ovarian failure by attenuating granulosa cell senescence and modulating the mtDNA-cGAS pathway
Hydroxychloroquine attenuates premature ovarian failure induced by cyclophosphamide chemotherapy through mechanisms that reduce cellular senescence and modulate mitochondrial DNA signaling in granulosa cells. This finding has direct implications for preserving reproductive longevity and ovarian function in women undergoing cancer treatment.
Engineering longevity with the ZEUGMA hyperbaric chamber
Hyperbaric oxygen therapy, traditionally confined to clinical medicine, is being deployed in performance and longevity settings through chambers like ZEUGMA, which operate at pressures enabling oxygen to dissolve into plasma at concentrations far exceeding atmospheric levels. The mechanism addresses tissue oxygen delivery and cellular repair, though evidence for durable benefits in healthy individuals remains under investigation.
Wearables may spot brain changes earlier
Continuous passive monitoring via consumer wearables can detect meaningful variability in cognitive and mood patterns over months, capturing environmental and physiological influences on brain function earlier than episodic clinical assessment. The strongest predictive signals—sleep quality, heart rate patterns, and environmental exposure—suggest brain health is fundamentally linked to systemic and environmental conditions rather than isolated neural function.
Gut microbes may influence GLP-1 drug response
Gut microbial composition significantly influences individual response to GLP-1 medications, with distinct bacterial patterns correlating to treatment efficacy and the ability of the microbiome to support metabolic signaling. This mechanism explains variable clinical outcomes and suggests microbiome profiling could predict responders before treatment initiation.
‘Peak performance’ culture is exhausting our nervous systems
Chronic pursuit of peak performance without adequate recovery locks the nervous system in a prolonged stress state, diverting resources from sleep, digestion, immunity, and cognitive function. This pattern drives burnout and disease rather than sustainable health, requiring deliberate recovery practices and calendar curation as foundational interventions.
Troculeucel may boost cognition, new Alzheimer’s data shows
NKGen Biotech's Troculeucel, a patient-derived natural killer cell therapy, shows early Phase 1 signals of cognitive improvement in moderate Alzheimer's disease, with reduced blood markers of brain inflammation correlating with enhanced memory and thinking performance. This represents a mechanistic shift from symptom management toward mobilizing endogenous immune defenses to address disease progression.
Biotech lands $45m to drug the undruggable
Unnatural Products raised $45 million to advance macrocyclic peptide therapeutics targeting intracellular protein interactions implicated in cardiometabolic, inflammatory, and age-related diseases. This technology addresses a critical gap in drug development by enabling selective modulation of previously inaccessible cellular pathways.
How Zinc Protects Injured Arteries From Accelerated Aging
Vascular injury triggers rapid nuclear deformation in arterial smooth muscle cells, accelerating cellular senescence through prelamin A accumulation. Zinc supplementation partially restores normal nuclear morphology by supporting the enzyme Zmpste24, which processes this senescence-driving protein.
Magnesium Deficiency Accelerates Gut Aging and Increases Susceptibility to Colitis
Magnesium deficiency accelerates intestinal aging and increases susceptibility to colitis by destabilizing cellular adhesion complexes. Population data from 182,213 individuals shows dietary magnesium intake of 334.7–420.0 mg/day significantly reduces risk of inflammatory bowel disease, irritable bowel syndrome, and related disorders.
Cross-Sectional and Longitudinal Associations Among Loneliness, Depression/Anxiety, and the Subjective and Chronological Age Difference in Older Adults
Loneliness and depression/anxiety in older adults correlate with feeling older than one's chronological age, with longitudinal evidence suggesting emotional distress may accelerate subjective aging. This relationship has direct implications for how psychological states influence biological aging trajectories.
#384 – Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer’s prevention
Obicetrapib, a CETP inhibitor, demonstrates cardiovascular benefits and potential neuroprotective effects against Alzheimer's disease—outcomes that distinguish it from four previous compounds in this drug class. The mechanism addresses both systemic lipid metabolism and cerebral amyloid pathology, making it relevant to multi-system longevity strategies.
Featured Cover
Adherence to sustainable dietary patterns moderates the accelerated biological aging associated with particulate matter exposure, suggesting that dietary quality can partially offset environmental pollutant burden at the cellular level. This finding indicates a modifiable pathway through which nutritional intervention may counteract oxidative stress and inflammatory cascades triggered by air pollution.
Regulation of Lipid Dysmetabolism and Neuroinflammation Progression Linked With Alzheimer's Disease Through Modulation of Dgat2
Dgat2, an enzyme controlling triglyceride synthesis, emerges as a critical regulator linking amyloid pathology to lipid accumulation and neuroinflammation in Alzheimer's disease. Suppressing Dgat2 in animal models restores cognitive function, synaptic integrity, sleep quality, and circadian rhythms while reducing neuroinflammatory signaling, indicating a conserved therapeutic target across species.
Adequacy, Availability, and Awareness of Alzheimer’s Disease Resources Among Extension Professionals in Texas: Is There an Urban-Rural Divide?
Rural Extension professionals report significant gaps in Alzheimer's disease resources and dementia literacy compared to urban counterparts, with disparities in access to educational materials, diagnostic support, and caregiver services. These findings identify a structural barrier to early detection and management of cognitive decline in populations already at higher risk due to demographic and healthcare infrastructure constraints.
An intriguing case of “exceptional resilience” against dementia
A 75-year-old carrier of a dominant Alzheimer's mutation remained cognitively intact, suggesting that genetic predisposition does not determine disease expression. This case indicates that protective mechanisms—possibly involving heat shock proteins and cellular stress response—can override genetic risk, with implications for understanding preventive intervention strategies in neurodegeneration.
MBX Biosciences reports 2025 results and advances endocrine pipeline
MBX Biosciences advanced its endocrine and metabolic pipeline with a successful FDA End-of-Phase 2 meeting for canvuparatide in chronic hypoparathyroidism, positioning a Phase 3 trial for 2026. The company's funding runway extends to 2029, supporting multiple programs targeting metabolic dysfunction and hormone regulation.
Pretzel Therapeutics presents PX578 data supporting POLG disease treatment
PX578, a first-in-class small molecule activator of mitochondrial DNA polymerase gamma, demonstrated preclinical efficacy in restoring mitochondrial DNA levels and cellular energy production across multiple POLG disease models. The compound addresses the underlying genetic defect in mitochondrial DNA depletion syndromes, for which no disease-modifying treatments currently exist.
Aspen wins official name for Parkinson’s cell therapy candidate
Aspen Neuroscience received WHO and AMA approval for the official name Sasineprocel for its autologous dopaminergic cell therapy derived from patient skin cells. The therapy aims to restore dopamine-producing neurons in Parkinson's disease without immunosuppression, currently in Phase 1/2a trials.
Cymbiotika partners with Ulta Beauty for nationwide retail rollout
Cymbiotika is expanding distribution through Ulta Beauty's 1,000+ stores, launching four liposomal supplements focused on cellular health, NAD+ production, detoxification, and recovery. The partnership reflects market demand for internal supplements that support skin health and systemic function.
Gut Bacteria Might Affect Cognition via the Vagus Nerve
Age-related cognitive decline involves microbiome remodeling, with Parabacteroides goldsteinii identified as a primary driver that suppresses neuronal activation in the hippocampus via the vagus nerve. Antibiotic treatment reverses the cognitive deficit even after it develops, establishing the microbiome as a modifiable mechanism rather than an irreversible consequence of aging.
Revive expands access to physical therapy via Orbit telehealth partnership
ReviveHealth integrated virtual physical therapy through Orbit Telehealth, consolidating therapy access within a single coordinated care platform alongside primary care, mental health, and pharmacy services. This addresses a structural barrier to rehabilitation—fragmented access—that undermines consistent participation in movement-based interventions critical to maintaining functional capacity and independence across the lifespan.
Renue by Science wins precision recovery & performance award
Renue by Science received recognition for its Total NAD+ Restoration Protocol, a multi-pathway supplement approach designed to address age-related NAD+ decline through enhanced precursor delivery, reduced NAD+ catabolism, improved mitochondrial efficiency, and cellular repair support. NAD+ restoration represents a targeted intervention in the metabolic foundation of cellular aging.
Clene reports full year 2025 results with ALS drug progress
Clene Inc. advanced CNM‑Au8, an investigational therapy targeting mitochondrial dysfunction in neurodegenerative diseases, with biomarker data showing statistically significant reductions in neurodegeneration markers linked to improved survival. The company narrowed its net loss to $26.2 million in 2025 and secured over $28 million in funding to support regulatory filings through 2027.
Serotonin Centers unveils medical longevity model for fitness industry
Serotonin Centers launched a medical longevity model enabling fitness facilities to integrate medically supervised services including hormone optimization, peptide therapies, and metabolic support within existing spaces. The turnkey approach addresses growing consumer demand for integrated health solutions that extend beyond traditional fitness training.
Theriva Biologics reports 2025 results and pipeline progress
Theriva Biologics reported 2025 operational results with $13.1 million in cash reserves and extended runway into Q1 2027, while advancing its lead oncology candidate VCN-01 toward pivotal trials for pancreatic cancer and retinoblastoma. The company licensed its recombinant enzyme asset to reduce development costs and focus capital on higher-potential oncology programs.
Lilly commits $500m in South Korea’s rise as longevity hub
Eli Lilly's $500 million commitment to South Korea's biotech ecosystem, alongside similar investments from Roche, signals pharmaceutical industry recognition of the country as an innovation hub rather than merely a market. These investments focus on startup incubation, clinical trial infrastructure, and research partnerships—accelerating the translation of discovery into therapeutic development.
Alveus bags $197 million in booming obesity drug race
Alveus Therapeutics raised $197 million in Series A funding to advance next-generation obesity treatments, including ALV-100, which combines two metabolic signaling pathways to achieve durable weight loss, and ALV-200, an amylin receptor agonist representing a potential frontier beyond current GLP-1 approaches. This capital deployment reflects the biomedical sector's recognition of obesity as a chronic metabolic disease requiring mechanistically distinct therapeutic strategies.
TMRW lands $7m to expand longevity clinics
TMRW, an Australian longevity platform, secured $7 million in seed funding to expand clinical services and deepen biological age assessment through epigenetic testing in partnership with TruDiagnostic. The company differentiates itself by analyzing approximately 1,700 biological data points and integrating clinical support alongside diagnostics, moving beyond dashboard-only models.
C2N Diagnostics expands Alzheimer’s blood testing to South Korea
C2N Diagnostics has launched blood-based Alzheimer's testing in South Korea through a partnership with BeauBrain Healthcare. The PrecivityAD2 test detects amyloid pathology with 91% accuracy and offers a less invasive, more accessible alternative to PET imaging for identifying cognitive impairment earlier in disease progression.
Seizure drug may halt Alzheimer’s early
Levetiracetam, an FDA-approved epilepsy drug, blocks production of amyloid-beta 42 by subtly altering protein trafficking within neurons—intervening decades before Alzheimer's symptoms emerge. This represents a shift from clearing existing plaques to preventing their formation at the source.
Study finds daily multivitamin can ease signs of biological aging
A two-year study of 958 adults aged 70+ found that daily multivitamin use slowed biological aging markers measured through epigenetic clocks, with the effect most pronounced in participants showing accelerated aging. While the slowdown was modest—measured in months rather than years—the consistent effect across multiple aging biomarkers suggests multivitamins may influence cellular-level processes relevant to healthspan rather than lifespan extension.
Vertex moves toward FDA filing for chronic kidney disease drug
Vertex Pharmaceuticals reported Phase 3 trial results showing povetacicept reduced proteinuria by 52% in IgA nephropathy patients, compared to 4.3% in placebo groups, with an FDA filing planned by March. This represents a shift toward upstream immune intervention in kidney disease, addressing the autoimmune dysfunction driving tissue damage rather than managing symptoms alone.
Glycative Stress Disrupts the Mitochondrial‐Lysosome Axis and Promotes Geroconversion in Aging Cardiomyocytes
Advanced glycation end products accumulate in cardiac mitochondria with age, impairing lysosomal function and mitochondrial quality control. This impaired clearance mechanism drives cellular senescence and represents a mechanistic link between cardiac aging and heart failure development.
Biologically Younger Individuals, as Identified by MARK‐AGE Biological Age Scores, Display a Distinct Favourable Blood Chemistry Profile Regardless of Age
Biological age, calculated from a 10-marker panel, correlates with HDL cholesterol, vitamin D, and immune function (CD4+ ratio) independently of chronological age. Subjects with lower biological age scores showed favorable values in these markers, suggesting they function as drivers of the aging process rather than mere correlates.
DeepStrataAge: an interpretable deep-learning clock that reveals stage- and sex-divergent DNA methylation aging dynamics
DeepStrataAge, a deep-learning model trained on DNA methylation patterns, identifies distinct aging trajectories between biological sexes and developmental stages, revealing that aging acceleration is not uniform across the lifespan. This sex- and stage-specific resolution improves the precision of biological age assessment and may refine risk stratification for age-related disease prevention.
Longitudinal changes in epigenetic clocks predict survival in the InCHIANTI cohort
Longitudinal acceleration in epigenetic clocks—independent of baseline epigenetic age—predicts mortality risk in the InCHIANTI cohort. The rate of change in multiple epigenetic clocks emerges as a more predictive mortality marker than epigenetic age alone, offering refined mortality risk stratification.
Multifunctionality of TIM-3: from immunological aging to pathological progression
TIM-3, an immune checkpoint protein, drives age-related immune dysfunction and contributes to neurodegeneration and brain tumors through promotion of immunosuppressive myeloid cells. Blocking TIM-3 represents a potential therapeutic approach to restore immune competence in central nervous system disease.
Urbanization, environment, and inflammaging: insights from sub-Saharan Africa
Urban environments in sub-Saharan Africa show accelerated inflammaging—chronic, low-grade systemic inflammation associated with aging—driven by environmental stressors including air pollution, pathogenic load, and dietary shifts. This research identifies modifiable environmental and lifestyle factors that influence the rate of immunological aging independent of chronological age.
Lifelong Motion Patterns Predict Lifespan
Research on killifish demonstrates that aging occurs in discrete stages rather than linear decline, with movement patterns in mid-life serving as a measurable predictor of remaining lifespan. This staged aging model suggests that locomotor capacity reflects underlying systemic vulnerability across multiple organ systems.
Xplore Program 2026: A Remote Summer Fellowship in Longevity
The Xplore Program is a fully remote summer fellowship designed to translate longevity interest into practical biotech experience through structured education and direct project placement with partner organizations. The program addresses a critical gap: making the pathway into longevity science explicit and accessible to talented individuals outside major biotech hubs.
Vitalist Bay 2026 Returns to Berkeley May 14–17
Vitalist Bay 2026, the world's largest longevity conference, returns to Berkeley May 14–17 with over 60 speakers and workshops spanning aging biology, AI, biotech translation, and investment. The event consolidates leading researchers, entrepreneurs, clinicians, and investors into a four-day intensive focused on accelerating the scientific and commercial infrastructure around human lifespan extension.
First 100 speakers revealed for The Longevity Show
The Longevity Show's inaugural speaker lineup of 100 experts signals the maturation of longevity science from academic niche to mainstream economic and cultural priority. The event's dual-track structure—pairing geroscientists with clinicians, entrepreneurs, and consumer health voices—reflects a recognition that extending healthspan requires translation from discovery into sustained behavioral change across populations.
AI predicts who will decline faster in Alzheimer’s
Machine learning models trained on routine clinic data predict individual rates of cognitive and functional decline in Alzheimer's disease and mild cognitive impairment with greater accuracy than population averages. Early identification of specific functional vulnerabilities—such as difficulty with finances or meal preparation—enables targeted interventions before independence is lost.
‘Age reversal is the only viable path for effective therapy’
Telocyte's founder argues that effective longevity intervention requires reversing aging at the cellular level rather than managing age-related diseases incrementally. The company is preparing a telomerase gene therapy trial in dogs, with the thesis that aging results from failed maintenance systems that can be reset rather than from inevitable biological decline.
AI app puts longevity data in your pocket
Human Longevity has launched a mobile application that consolidates clinical data, biomarkers, genetic information, and imaging results into a continuous health record accessible to users. The platform uses AI to identify patterns across longitudinal data, shifting preventive health assessment from episodic annual checkups to real-time risk monitoring and interpretation.
Celularity inks $35m deal for longevity push
Celularity secured $35 million in non-dilutive funding through a licensing agreement for its placental biomaterials portfolio, allowing the company to refocus resources on therapies targeting fundamental aging mechanisms while maintaining manufacturing and royalty streams. This capital structure reflects a strategic shift within regenerative medicine toward specialization in aging biology rather than symptomatic disease treatment.
First patients dosed in EyePoint’s diabetic eye trials
EyePoint Pharmaceuticals has begun Phase 3 trials for DURAVYU, a sustained-release ocular insert designed to treat diabetic macular edema with dosing every six months rather than every few weeks. The therapy addresses a significant treatment burden in a condition affecting 28 million people globally, where current anti-VEGF injections leave two-thirds of patients with persistent active disease despite frequent interventions.
The Many Dangers of 7-Ketocholesterol
7-ketocholesterol (7KC), an oxidized cholesterol byproduct formed through oxidative stress, accumulates in atherosclerotic lesions and impairs macrophage function, mitochondrial integrity, and neuronal survival. Its role as a biomarker for cardiovascular and neurological damage remains clinically underutilized due to the absence of standardized measurement techniques.
Celularity secures $35m license deal to back longevity strategy
Celularity licensed its placental-derived biomaterials portfolio for up to $35 million in non-dilutive capital, allowing the company to redirect resources toward cell therapies targeting senescence, inflammation, and tissue degeneration. This repositioning reflects a strategic shift from broad biomaterials commercialization to targeted longevity interventions.
Building on Preserved Capabilities of People Living With a Neurocognitive Disorder: Participatory Action Research for the Implementation of Cognitive Strategies in a Seniors’ Residence
Cognitive strategy interventions implemented through participatory action research enable people with neurocognitive disorders to maintain engagement in meaningful activities and preserve dignity. The approach leverages procedural memory—the capacity to retain learned motor and behavioral patterns—as a foundation for functional preservation despite cognitive decline.
MBX Biosciences appoints new chief business officer
MBX Biosciences appointed Karen Basbaum as Chief Business Officer to advance its pipeline of precision peptide therapies for metabolic and endocrine disorders. The appointment reflects the company's focus on clinical-stage development of treatments for obesity and post-bariatric complications.
Minerva Neurosciences reports 2025 financial results and pipeline update
Minerva Neurosciences advanced its clinical pipeline for central nervous system disorders, securing financing to support a Phase 3 trial of roluperidone for schizophrenia's negative symptoms and continuing development of MIN-301 for Parkinson's disease. The company's progress reflects ongoing efforts to target neurochemical pathways involved in mood, cognition, and motor control.
Cognito Therapeutics appoints Thomas Fagan to lead Alzheimer’s portfolio
Cognito Therapeutics appointed Thomas Fagan, an executive with 25+ years in Alzheimer's commercialization, to lead development of Spectris—a non-invasive neuromodulation platform designed to preserve cognitive function and slow brain atrophy in early-stage Alzheimer's disease. This appointment signals movement toward clinical milestones and market readiness for a mechanism distinct from amyloid-targeting approaches.
Testing the redox theory of aging under parasitism
Parasitic infection accelerates oxidative stress and aging markers in host organisms, providing empirical support for redox-based aging mechanisms. This finding illuminates how chronic pathogenic burden compounds systemic dysfunction and accelerates cellular deterioration through reactive oxygen species accumulation.
Fasting mimetic shows metabolic effects in trial
A randomized controlled trial of a fasting mimetic formulation in overweight older adults with elevated HbA1c showed reductions in LDL particle number, oxidized LDL, and fasting glucose over eight weeks. The compound—a blend of spermidine, nicotinamide, palmitoylethanolamide, and oleoylethanolamide—reproduced several cardiometabolic signatures associated with fasting without dietary restriction, though durability beyond the study period remains undemonstrated.
Breakthrough scan differentiates LATE from Alzheimer’s
PET and MRI imaging can now differentiate LATE (limbic-predominant age-related TDP-43 encephalopathy) from Alzheimer's disease in living patients, addressing a diagnostic gap that has resulted in widespread misclassification. Since LATE arises from different pathology (TDP-43 protein clumping) than Alzheimer's (amyloid and tau accumulation), accurate differentiation is essential for appropriate treatment selection and prognosis.
GLP-1 drugs hint at protection against neurodegeneration
GLP-1 receptor agonists show mechanistic promise against neurodegeneration through multiple pathways—improved mitochondrial function, enhanced cellular cleanup, and reduced inflammation—but human evidence remains preliminary, with mixed cognitive outcomes in early trials and inconsistent results across disease types.
Capriroso launches platform for athlete longevity
Capriroso's platform interprets biometric data across weeks and months rather than daily snapshots, helping endurance athletes recognize long-term physiological patterns and make training decisions based on cumulative stress and recovery trends. This approach addresses a gap where abundant data has not improved understanding, potentially extending athletic lifespan through sustainable training practices.
People With Positive Outlooks Have Better Aging Outcomes
A longitudinal study of over 11,000 adults aged 65 and older found that 45% showed improvement in cognitive and/or physical functioning over 12 years, with positive age-related beliefs predicting these gains. This challenges the pervasive assumption that chronological aging inevitably produces decline and demonstrates that improvement remains physiologically possible in later life.
Immunis licenses Parkinson’s dyskinesia treatment candidate from Toray
Immunis has licensed IMM02-KORA, a drug candidate targeting L-DOPA-induced dyskinesia in Parkinson's disease patients, with preclinical data showing symptom reduction in animal models. The therapy addresses a significant clinical problem: involuntary movements that develop in a large proportion of patients on standard Parkinson's treatment, limiting functional capacity.
Allosteric Bioscience targets longevity research using AI and quantum computing
Allosteric Bioscience is using AI and quantum computing to model molecular mechanisms of aging, targeting pathways including Lamin A, tryptophan metabolism, DNA repair, and mitochondrial function. The approach aims to identify modulators that could reduce age-related disease and extend lifespan.
Lineage Cell Therapeutics reports higher revenue in 2025 results
Lineage Cell Therapeutics reported $14.6 million in total revenue for 2025, a 54% increase from 2024, driven primarily by milestone achievements in a Roche collaboration and research partnerships. The company's fourth-quarter performance showed net income of $0.9 million compared with a net loss of $3.3 million in the prior year, though full-year results reflected a net loss of $63.5 million largely attributable to non-cash warrant liability remeasurements and asset impairments.
MBX Biosciences outlines Phase 3 plan for hypoparathyroidism therapy
MBX Biosciences has completed Phase 2 discussions with the FDA and plans to initiate a Phase 3 trial of canvuparatide, a once-weekly parathyroid hormone replacement therapy for chronic hypoparathyroidism. The trial will evaluate whether patients can achieve normal calcium levels while becoming independent from conventional therapy, addressing a condition that impairs calcium regulation and mineral metabolism.
GenSight Biologics updates early access programs for LUMEVOQ therapy
GenSight Biologics is advancing LUMEVOQ (GS010), a gene therapy targeting ND4 mitochondrial mutations in Leber hereditary optic neuropathy, through early access programs in France, Israel, and the United States while conducting the REVISE dose-ranging clinical study. This represents progress toward treating a rare genetic form of progressive vision loss by addressing the underlying mitochondrial dysfunction.
WELL Health owned Wisp launches longevity care suite
Wisp, a telehealth platform owned by WELL Health, launched a longevity care suite offering glutathione, NAD+, and low-dose naltrexone to support cellular energy, immune function, and biological repair in women. The initiative addresses gaps in aging care during perimenopause and menopause through clinician-guided, asynchronous consultations and personalized treatment adjustments.
C2N Diagnostics partners with Codex Genetics to expand Alzheimer’s testing in Hong Kong
C2N Diagnostics and Codex Genetics are expanding access to PrecivityAD2, a blood test measuring amyloid biomarkers to assess Alzheimer's risk in asymptomatic or early-symptomatic individuals. Early detection via non-invasive biomarker assessment enables intervention before cognitive decline becomes clinically apparent, shifting Alzheimer's management from reactive to preventive.
Gordian Bio unveils scalable in‑vivo screening platform preprint
Gordian Bio describes a scalable in-vivo mosaic screening platform that uses barcoded CRISPR libraries and single-cell readouts to establish causal gene-disease relationships in living organisms. This approach accelerates therapeutic target discovery by testing multiple genetic perturbations simultaneously, reducing experimental variation and improving efficiency compared to traditional methods.
GenSight Biologics raises nearly €1.7M to support gene therapy programs
GenSight Biologics secured €1.7 million in funding to advance gene therapy programs targeting inherited retinal and mitochondrial diseases, with lead support from existing shareholders Advent France Biotechnology and RA Capital Management. The capital will fund clinical development of GS010/LUMEVOQ for Leber hereditary optic neuropathy and operational milestones through 2026.
Amydis lands NIA funding to detect ALS in the eye
Amydis has secured $2.5 million in Phase 2 NIH funding to develop a non-invasive eye-imaging technology that detects TDP-43, a protein biomarker present in over 97% of ALS cases. Early detection through a simple retinal scan could compress the current 9-12 month diagnostic timeline and enable earlier therapeutic intervention in a disease where time is critical.
Exploring Home and Community-Based Service Needs Among Rural Family Caregivers of Older Adult US Veterans
Rural family caregivers of aging veterans face escalating demands without adequate access to home and community-based services, creating a structural barrier to sustained caregiving capacity. The research identifies that caregiver health and service availability are interdependent factors determining whether informal care systems can function long-term in underserved populations.
Stroke in persistent chronic kidney disease condition alters innate-immunity to escalate mitochondrial dysfunction and aging
Stroke in the context of chronic kidney disease triggers immune dysregulation that accelerates mitochondrial dysfunction and aging processes. This cascade reveals how organ system failure in one area can compromise cellular energy production and immunity simultaneously, with significant implications for longevity in populations with renal compromise.
Microfluidics device recovers oocytes for IVF
A microfluidics device enables recovery of immature oocytes from ovarian tissue, expanding the pool of viable eggs available for fertility preservation and IVF. This technology addresses a critical bottleneck in reproductive medicine by recovering oocytes that conventional methods miss, with direct implications for fertility outcomes across age groups.
Microglia protein profiles in CSF across Alzheimer’s disease clinical stages
Analysis of microglial proteins in cerebrospinal fluid identifies distinct molecular signatures across Alzheimer's disease stages, offering potential biomarkers for earlier detection and disease progression tracking. These markers reflect immune cell activation patterns that precede symptomatic decline, enabling more precise stratification of disease trajectory.
[Review] Guidelines and tools to assess appropriateness of diuretic prescribing and aid deprescribing: a systematic review
Long-term diuretic use without clear indication increases adverse events including electrolyte disturbances, renal dysfunction, hypotension, falls, and reduced quality of life in older adults. A systematic review of 41 clinical resources identified 184 recommendations for identifying inappropriate chronic diuretic use and supporting deprescribing in patients with multimorbidity and polypharmacy.
MindImmune lands ADDF funding to harness the immune system against Alzheimer’s
MindImmune Therapeutics secured $5 million from the Alzheimer's Drug Discovery Foundation to advance MITI-101, a therapeutic targeting peripheral immune cell migration into the brain rather than amyloid or tau pathology. The approach addresses neuroinflammation as a driver of neurodegeneration, with preclinical evidence showing that blocking CD11c-positive immune cells reduces synaptic deterioration markers.
Novo’s triple-G obesity drug hits 19.7% loss in China trial
A triple-agonist obesity drug (UBT251) achieved 19.7% weight loss over 24 weeks in a Phase 2 trial, with concurrent improvements in glucose, blood pressure, and lipid profiles. This represents a shift toward multi-system metabolic intervention rather than single-pathway hormone modulation, with implications for reducing chronic disease burden across the lifespan.
Niagen Bioscience secures patent for NR injections
Niagen Bioscience secured a US patent protecting intravenous and injectable formulations of nicotinamide riboside (NR), a NAD+ precursor molecule that declines with age and cellular stress. The patent extends protection through 2044 and positions the company to dominate clinical delivery of NAD+ boosters, a market rapidly expanding across wellness clinics.
Klotho unveils AI-powered aging clock
Klotho Neurosciences has developed AI-powered genomics tests that measure biological age through DNA methylation and mRNA analysis of longevity-associated genes. This approach enables more precise stratification in clinical trials for neurodegenerative diseases, reducing confounding variables that arise when chronological and biological age diverge.
Scientists Successfully Freeze and Rewarm Mouse Brain Slices
Researchers successfully vitrified and rewarmed mouse brain tissue while preserving neuronal structure and basic synaptic function. This represents the first demonstration of functional recovery in mammalian brain tissue after cryopreservation, advancing a technique that could eventually enable organ preservation for transplantation and long-term storage.
The mouth-body connection: why oral health matters for longevity
Oral health functions as a systemic gateway affecting breathing mechanics, sleep quality, inflammation, and metabolism rather than existing as an isolated dental concern. Optimizing breathing patterns, airway function, and oral microbiota through evidence-based dental and postural interventions produces measurable improvements in cardiovascular health, sleep architecture, and immune function.
Novel PMVs/ZIP4/Zinc/Prelamin A Axis Promotes Nuclear Dysmorphism and Vascular Aging in Humans and Rodents Post‐Injury: Effective Treatment With Platelet Membrane‐Coated ZIF‐8 Nanoparticles
Surgical and interventional injury triggers vascular aging through a zinc-dependent mechanism involving platelet-derived microvesicles, zinc transporter deficiency, and prelamin A accumulation in vascular smooth muscle cells. Platelet membrane-coated zinc nanoparticles effectively reverse this cascade, offering a targetable pathway for post-injury vascular dysfunction.
Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming
Senotherapeutics—strategies that eliminate or reprogram senescent cells—represent a shift from broad-spectrum senolytic approaches toward precision interventions that target specific cell types and contexts. This progression directly addresses a fundamental mechanism of aging, offering potential to extend healthspan by restoring cellular function rather than relying solely on senescent cell elimination.
Simultaneous spatial transcriptomics and morphology profiling as tools to explore how microglia change with age
Microglia—the brain's resident immune cells—exhibit distinct transcriptional patterns and morphological changes with age, with subcellular mRNA localization directly influencing their functional capacity. This work establishes how aging alters the molecular foundation of neuroinflammation, a process central to cognitive decline and neurodegenerative disease progression.
Forever Young explores the longevity revolution
A new documentary translates geroscience research into accessible language for public audiences, emphasizing that lifestyle and environmental factors—not genetic destiny—are the primary drivers of aging outcomes. This shift from genetic determinism to behavioral agency represents a critical moment in moving longevity science from laboratory to practical application.
Startup targets ‘untreatable blindness’ with bionic eye system
ReVision Implant received FDA Breakthrough Device designation for a visual cortical prosthesis that restores functional vision by directly stimulating the visual cortex with microelectrode arrays, addressing severe blindness cases where retinal implants are ineffective. This advancement extends neuroprosthetic intervention to patients with near-total vision loss, expanding the population that could benefit from vision restoration technology.
Sleep is a top health priority, but not a practice, says survey
A global survey of 30,000 people reveals that 53% now rank sleep as the most important health behavior for longevity—ahead of diet and exercise—yet over half report consistent sleep only four nights per week or less. The gap between awareness and action persists despite rising wearable adoption, with only 23% of respondents having consulted healthcare providers about chronic sleep issues despite recognizing its centrality to health.
Transposon’s $22m ARPA-H award to test aging-fighting drug
Transposon Therapeutics received a $22 million ARPA-H grant to study TPN-101, a drug designed to inhibit LINE-1 retrotransposon activity and slow fundamental aging processes rather than treat individual diseases. The approach targets age-related inflammation driven by DNA elements that become dysregulated with age, potentially extending healthspan across multiple conditions simultaneously.
A Review of How the Heart Ages
The heart undergoes progressive cellular dysfunction with age, driven by mitochondrial impairment, cellular senescence, and fibrosis, with heart failure prevalence increasing from 1% in those under 55 to over 10% in those over 70. Understanding these mechanisms is essential for developing targeted interventions against age-related cardiac disease.
Oura launches AI model for women’s health insights
Oura has developed a proprietary AI model specifically designed to contextualize women's health questions using personal biometric data from its wearable ring. The system integrates clinical evidence with continuous physiological signals to provide personalized guidance rather than generic web-based information, addressing a gap in how most AI tools handle women's hormonal and reproductive physiology.
Altered Cytokine‐Induced STAT3 and STAT5 Activation of Peripheral T Follicular Helper Cells Contributes to Vaccine‐Non‐Responsiveness in Aging and HIV
Aging and HIV infection shift peripheral T follicular helper cell signaling from IL-21–STAT3 toward IL-2–STAT5 activation, impairing the immune response to influenza vaccination. This signaling imbalance represents a measurable immune mechanism underlying vaccine non-responsiveness in older adults and people with HIV.
[Articles] Repeated measures of physical activity before dementia diagnosis in community-dwelling older adults: a longitudinal study
Repeated measures of physical activity in community-dwelling older adults reveal that the protective association with dementia risk varies depending on timing relative to diagnosis, suggesting that activity patterns in the years immediately preceding cognitive decline may be more predictive than earlier lifetime activity. This finding reframes physical activity from a static risk factor into a dynamic variable whose relevance to dementia prevention depends on proximity to disease onset.
Tai Chi and Qigong to Enhance Cognitive Function in Community-Dwelling Older Adults: Evidence from a Systematic Review and Meta-Analysis
Tai Chi and Qigong demonstrate measurable cognitive benefits in older adults through systematic review and meta-analysis, with effect sizes comparable to established interventions. This evidence supports non-pharmacological approaches to address age-related cognitive decline at the population level.
A Multi‐Organ Atlas Links Gut Microbial Metabolites to Systemic Redox Changes in Aging Mice
Gut microbial metabolites drive systemic aging through a conserved signature of depleted protective compounds (lysophosphatidylcholines) and accumulated pro-oxidative catabolites (TMAO, indole-3-acetic acid), which propagate redox stress across liver, lung, and brain. Microbiome interventions that restore this metabolic balance reverse key aging phenotypes and enhance antioxidant capacity, establishing the gut-metabolite axis as a modifiable target for extending healthspan.
#383 ‒ AMA #81: Biological aging tests, longevity training, emerging therapies, GLP-1 RAs, sun exposure, and more
This AMA addresses multiple longevity domains: biological aging biomarkers, exercise protocols for longevity, emerging therapeutic approaches, GLP-1 receptor agonists, and sun exposure risk-benefit profiles. The discussion emphasizes that evidence-based interpretation of these tools requires distinguishing between mechanistic plausibility and demonstrated clinical outcomes.
Correction to “An Ad Libitum‐Fed Diet That Matches the Beneficial Lifespan Effects of Caloric Restriction but Acts via Opposite Effects on the Energy‐Splicing Axis”
A correction to a study examining how ad libitum feeding can extend lifespan through mechanisms opposite to caloric restriction, particularly involving energy-splicing pathways. This finding challenges the assumption that caloric restriction is the only dietary approach to lifespan extension and suggests multiple metabolic routes can achieve similar longevity outcomes.
The Use of Purposeful Physical Settings in Group-Based Psychosocial Interventions for Older Adults: A Scoping Review of Study Protocols
Physical environment design in group-based psychosocial interventions for older adults remains understudied despite potential to enhance engagement and outcomes. The review identifies gaps in how sensorial and spatial elements are systematically integrated into interventions targeting psychological resilience and social connection.
Epigenetic aging and cancer incidence in a German cohort of older adults
Epigenetic age acceleration—measured through DNA methylation patterns—independently predicts cancer incidence in older adults, even after accounting for chronological age and established risk factors. This biomarker offers a quantifiable proxy for biological aging that may identify individuals at elevated cancer risk before conventional screening protocols would.
Aged Male Mice Remain Glucose Tolerant Despite Increased Energy Storage Efficiency Favoring Diet‐Induced Obesity
Aged male mice maintain glucose tolerance despite accumulating more fat on a high-fat diet than younger counterparts, a metabolic uncoupling driven by increased energy storage efficiency and reduced lipid turnover. This finding indicates that obesity and glucose dysregulation diverge with age, presenting distinct intervention targets for metabolic health in older populations.
Methylmalonic Acid, an Aging‐Associated Metabolite, Accelerates Intervertebral Disc Degeneration by Inducing Disc Vascularization via the CCL7/JAK2‐STAT3/VEGF Signaling Axis
Methylmalonic acid accumulates in aging intervertebral discs and drives degeneration through pathological vascularization via the CCL7/JAK2-STAT3/VEGF signaling pathway. VEGF receptor inhibition slowed disc degeneration in preclinical models, establishing vascularization as a therapeutic target in disc disease.
A failed endpoint is not a failed technology
GRAIL's cancer screening trial missed its primary composite endpoint, but subgroup analysis reveals meaningful detection rates in specific cancer types, indicating the technology may have clinical value despite the headline failure. Understanding what the data actually shows versus what was reported requires interpreting signal-to-noise in early detection research.
The Immune‐Autonomic Interface in Aging: Baseline Immune Profile Shapes Cardiac Autonomic Response to Exercise
Baseline immune cell profiles in older adults predict how their heart rate variability responds to acute exercise stress. This immune-autonomic relationship reveals why individuals show heterogeneous physiological resilience during aging, informing personalized intervention strategies.
Physical Fitness Dynamics Shape Immune Remodeling in Healthy Aging: A 3‐Year Longitudinal Study
In clinically healthy older adults tracked over three years, declining physical fitness—independent of reported activity levels—drove immune remodeling toward senescent and regulatory T cell phenotypes, without systemic inflammation. Physical fitness emerges as a modifiable determinant of immune aging trajectory and resilience.
Longevity and disease insights now in 20/20 BioLabs blood test
20/20 BioLabs launched OneTest for Longevity, a blood test combining inflammatory biomarkers, lifestyle data, and AI to identify chronic disease risk before clinical symptoms emerge. The platform translates biomarker patterns into actionable dietary and lifestyle modifications, addressing inflammation and stress response as primary drivers of aging and age-related disease.
Toray out-licenses novel Parkinson’s therapy
Toray has licensed TRK-820 (IMM02-KORA), a selective kappa opioid receptor agonist, to Immunis for development as a treatment for L-dopa-induced dyskinesia in Parkinson's disease. This approach addresses a fundamental trade-off in Parkinson's management: the involuntary movements that emerge as a side effect of the dopaminergic therapy that initially restores function, with direct implications for preserving functional capacity and quality of life in aging populations.
Partnership brings new AI model promising faster drug discovery
Insilico Medicine and Liquid AI have developed LFM2-2.6B-MMAI, a compact AI model that performs drug discovery tasks with efficiency matching much larger systems while maintaining data privacy through on-premise deployment. This acceleration of early-stage compound identification and optimization directly shortens timelines for therapies targeting age-related diseases.
Science Corp lands $230m to commercialize vision restoration chip
Science Corporation has raised $230 million to commercialize PRIMA, a wireless retinal implant designed to restore central vision in patients with advanced macular degeneration and inherited retinal diseases. The device represents the first brain-computer interface system to achieve clinical efficacy in restoring functional form vision, with European launch expected in 2024.
The curious virality of billionaire mortality data
A study analyzing mortality patterns in billionaires achieved unexpected viral reach—450,000+ views across social platforms in three days—by combining universal appeal (wealth and mortality), counterintuitive details (helicopter crashes, suicides), and data visualization design. The analysis reveals critical lessons about communicating longevity research to audiences beyond the scientific community.
Fat Composition Affects T Cell-Mediated Immunity
The ratio of polyunsaturated to monounsaturated fatty acids in the diet determines T cell susceptibility to ferroptosis, an iron-dependent form of cell death that regulates anti-tumor immunity, antibody production, and immune memory. Mice fed diets with low PUFA-to-MUFA ratios retained significantly more functional T cells and mounted stronger immune responses.
Sleep rhythms and dementia risk link emerges
Chronic circadian disruption triggers structural changes in microglia, shifting them toward an inflammatory, stress-primed state that impairs their ability to clear neural debris. This mechanism may represent a primary driver of brain aging and dementia risk decades before cognitive symptoms emerge, with emerging research exploring whether stem cell-derived extracellular vesicles can intercept this inflammatory cascade.
Your Mindset is the Secret to Aging in Reverse
A longitudinal study found that 45% of older adults show cognitive improvement over a decade, with positive age-related beliefs associated with better outcomes. This challenges the assumption that cognitive decline is inevitable with age and suggests mindset-dependent mechanisms may influence cognitive trajectory.
Cortechs.ai partners with Siemens Healthineers to expand NeuroQuant access
Cortechs.ai and Siemens Healthineers have partnered to integrate NeuroQuant, an FDA-cleared AI neuroimaging tool, into clinical workflows for automated brain lesion tracking and volumetric quantification. This expands clinician access to objective, longitudinal brain imaging data for monitoring neurological disease progression and treatment response, including anti-amyloid therapies for Alzheimer's disease.
Alnylam Pharmaceuticals gains genomic data access under Helix deal
Alnylam Pharmaceuticals secured access to Helix's large-scale genomic and clinical datasets to identify novel RNA interference therapeutic targets. This partnership accelerates precision medicine development by coupling genetic sequencing with 13 years of longitudinal health records, enabling systematic target discovery across disease areas.
Niagen Bioscience reports 30% sales growth in 2025
Niagen Bioscience reported 30% year-over-year sales growth to $129.4 million in 2025, with net income more than doubling and gross margins expanding 250 basis points. The growth was driven by increased Tru Niagen product sales and ingredient revenue, supported by e-commerce expansion and market penetration.
Decreased Glucose Metabolism and Declined Chaperones Are Unique Features Required for the Survival of Senescent Fibroblasts and Pyruvate Dehydrogenase Is a Potent Senolytic Target
Senescent fibroblasts depend on reduced glucose metabolism and maintained chaperone proteins for survival. Inhibiting pyruvate dehydrogenase selectively eliminates senescent cells, including therapy-induced senescent cancer cells, with synergistic enhancement when combined with chaperone inhibition.
A glycolytic metabolite puts the brakes on cGAS-driven aging
Phosphoenolpyruvate, a glycolytic metabolite, suppresses cGAS-driven inflammation through a direct molecular interaction. The age-related decline in PEP availability explains the transition from metabolic stability to chronic inflammation and neurodegeneration.
Mining the prodrome of neurodegeneration
Transformer-based analysis of electronic health records identified five distinct subtypes of Alzheimer's and Parkinson's disease, each with unique clinical trajectories, comorbidities, and genetic profiles. This stratification approach enables more precise disease understanding and potentially more targeted intervention strategies across the neurodegenerative disease landscape.
Dietary restriction in aging and longevity
Dietary restriction demonstrates geroprotective effects across species through multiple molecular pathways, though human data remains inconsistent and mechanistic understanding incomplete. This class of intervention represents a critical reference point for evaluating longevity strategies, particularly in identifying which downstream mechanisms drive aging resistance versus which reflect caloric reduction alone.
The glycolytic metabolite phosphoenolpyruvate restricts cGAS-driven inflammation to promote healthy aging
Phosphoenolpyruvate, a glycolytic metabolite, suppresses cGAS-STING-driven inflammation and improves cognitive function in Alzheimer's disease models while correlating with healthy aging markers in humans. This identifies a metabolic checkpoint that regulates innate immune signaling during aging.
Is neurodegeneration a systemic metabolic condition?
Vesalic's discovery identifies a systemic metabolic dysfunction marked by altered lipid composition in circulating extracellular vesicles in ALS patients' blood. This reframes neurodegenerative diseases as downstream consequences of upstream metabolic abnormalities rather than purely neurological conditions localized to the brain, with implications for earlier detection and intervention across multiple neurodegenerative pathologies.
Healthspan Horizons aims to map healthy aging
The Buck Institute launched Healthspan Horizons, a federated research initiative that integrates continuous real-world health signals from wearables and lifestyle tracking with periodic deep biological analyses to detect disease risk years before clinical diagnosis. The program positions data density and longitudinal measurement as infrastructure for shifting medicine from reactive treatment to anticipatory intervention.
[Articles] Incidental findings and duty-of-care protocols in cardiovascular magnetic resonance among older adults: a prospective population-based study from MyoFit46
Cardiovascular magnetic resonance imaging in adults over 75 reveals frequent incidental findings, demonstrating that large-scale aging cohorts require structured protocols for identifying, communicating, and managing unexpected discoveries. This work establishes a baseline for governance frameworks in gerontological research.
Lancôme ties up with Timeline to target skin’s biological age
Lancôme and Timeline have partnered to develop a skincare line using urolithin A (Mitopure), a molecule that enhances mitochondrial function in skin cells to address aging at the cellular level rather than merely treating visible signs. This represents a shift in luxury skincare from cosmetic coverage to supporting long-term cellular vitality and resilience.
Cognitive toolkit detects early Alzheimer’s signs
Researchers developed a Mandarin-language cognitive toolkit to detect early Alzheimer's signs in older Chinese Americans, addressing diagnostic gaps created by language and cultural bias in English-based assessments. The validated tests correlate with English measures and early blood-based biomarkers, enabling earlier intervention and broader research participation in underserved communities.
Avaí Bio–Austrianova’s longevity protein program enters production
Avaí Bio and Austrianova have begun GMP-compliant production of a Master Cell Bank for genetically modified cells engineered to overexpress α-Klotho, a protein associated with improved cognitive resilience and organ function in aging. This transition from research to scalable manufacturing represents a critical step toward clinical cell therapy delivery for age-related disease.
How Inflammaging Makes Pneumonia Worse in Mice
Aging impairs the rapid recruitment and metabolic function of neutrophils during pneumonia, a decline driven by chronic inflammation and cellular senescence that can be partially reversed by blocking TNFα. This mechanism explains age-related vulnerability to infection and identifies a potential intervention point.
Cognito lands $105m for sensory stimulation Alzheimer’s therapy
Cognito Therapeutics raised $105 million to advance Spectris, a non-invasive device delivering synchronized visual and auditory stimulation designed to restore disrupted neural oscillations in Alzheimer's disease. Prior feasibility data showed slowed cognitive decline and 69% reduction in brain volume loss, with a 673-participant pivotal trial now fully enrolled and expected to yield results that could support regulatory submission in 2027.
The Immune Cell Atlas of “Longevity Molecular Tag”: Identification of Principal Immune Cell Subsets and Their Underlying Molecular Regulatory Mechanisms
Centenarians maintain immune homeostasis through selective enhancement of cytotoxic immune cells (NK cells, CD8+ T cells, γδ T cells) paired with suppression of inflammatory pathways in adaptive immune populations. This remodeling of immune composition represents a compensatory adaptation mechanism that extends health span and informs potential interventions against immunosenescence.
Chronic kidney disease market set for strong growth through 2034
The global chronic kidney disease market is projected to expand significantly through 2034, driven by rising prevalence linked to aging, diabetes, and hypertension, alongside advances in diagnostic biomarkers and emerging therapeutic combinations. Early detection and novel treatment options directly influence outcomes in a disease affecting 82 million people across major developed markets.
Insilico Medicine and Liquid AI partner to build science‑oriented AI models for drug discovery
Insilico Medicine and Liquid AI are developing specialized AI foundation models to accelerate drug discovery by improving molecular prediction, biological activity forecasting, and compound design. This partnership demonstrates how computational efficiency in scientific AI can reduce timelines for therapeutic development while making tools accessible across the research community.
Cancer incidence and mortality trends among older adults
Cancer incidence rates in adults over 65 have stabilized or declined in recent decades, while mortality rates continue to improve across most cancer types. This shift reflects both earlier detection and advances in treatment efficacy, with profound implications for understanding aging and disease progression in the longest-lived populations.
Early mitophagy activation by Urolithin A prevents, but late activation does not reverse, age-related cognitive impairment
Urolithin A activates mitophagy—the removal of damaged mitochondria—and prevents age-related cognitive decline when initiated early, but fails to reverse existing cognitive impairment when treatment begins after decline has already occurred. This temporal dependency defines a critical window for intervention in age-related neurodegeneration.
ACSS2 is essential for myelination via maintenance of the OPC population
ACSS2, an enzyme that regulates histone acetylation, maintains the oligodendrocyte precursor cell pool essential for myelin formation. Acetate supplementation restores myelination capacity after aging or injury, suggesting a metabolic lever for preserving neural insulation and signal transmission across the lifespan.
[Articles] Multidomain post-stroke cognitive impairment: development and validation of a clinical prediction model
Stroke-specific cognitive prediction models that assess multidomain impairment offer more accurate prognostic value than general cognitive decline models. The binary and continuous versions developed in this research demonstrate generalisability across diverse stroke populations and warrant further domain-specific refinement.
Longevity law finds its footing
As longevity ventures mature from research-driven enterprises to scalable commercial platforms, specialized legal frameworks become essential infrastructure. The establishment of dedicated longevity legal practices signals that regulatory clarity and compliant business model design are now rate-limiting factors for sector growth, not biology itself.
Richter sharpens ovarian aging focus following Celmatix asset deal
Gedeon Richter acquired Celmatix's women's health portfolio, adding programs targeting ovarian aging, endometriosis, and fertility dysfunction. This transaction reflects growing recognition that ovarian function is a systemic health determinant and an investable axis within longevity science.
Annovis CEO eyes spring breakthrough for Alzheimer’s drug
Annovis Bio's buntanetap has cleared a critical safety checkpoint in its Phase 3 Alzheimer's trial, with the company expecting to reach the FDA's 1,500-patient enrollment threshold by spring 2025. The therapy aims to slow disease progression rather than merely manage symptoms, representing a mechanistic shift in how neurodegenerative decline might be addressed.
WHOOP enters $34.5m ARPA-H-backed bid to quantify aging
WHOOP has joined a $34.5 million Stanford-led research initiative to develop the first FDA-grade Intrinsic Capacity score, a predictive model designed to quantify functional healthspan and forecast major health outcomes up to 20 years in advance. The THRIVE coalition integrates continuous wearable physiological data with clinical biomarkers and functional assessments to measure resilience and detect early shifts toward vulnerability before disease manifests.
Resistance Exercise Training Slows Down Brain Aging
One year of heavy resistance training slowed brain aging by approximately 1.4 years compared to controls, with effects persisting one year after training cessation. Moderate-intensity resistance training showed smaller but measurable benefits, suggesting a dose-response relationship between exercise intensity and brain age deceleration.
Science Corp and Neurosoft unite to speed brain-computer care
A partnership between Science Corporation and Neurosoft Bioelectronics reduces brain-computer interface development costs from $75–100 million to under $5 million, accelerating clinical adoption of therapies for neurological conditions including epilepsy and tinnitus. For longevity practitioners, this infrastructure advancement enables faster restoration of neurological function and cognitive independence—essential dimensions of healthspan that outlive lifespan alone.
Mimio Health trial shows fasting‑mimetic delivers benefits without dieting
Mimio Health's fasting-mimetic therapy produced biomarker changes consistent with fasting physiology—including improved metabolic markers and enhanced fat metabolism—without dietary modification. The intervention was well tolerated and represents a pharmacological approach to accessing metabolic benefits traditionally associated with caloric restriction.
Cenegenics expands advanced plasma exchange services in Beverly Hills
Cenegenics has introduced selective plasma exchange technology designed to remove inflammatory proteins, metabolic byproducts, and environmental toxins while preserving beneficial plasma components. The service positions itself as a preventative intervention for individuals managing chronic environmental exposures and systemic inflammation.
XellSmart gets fourth consecutive IND clearances for iPSC cell therapy trials
XellSmart has secured IND clearance for a Phase I/II trial of iPSC-derived neuron progenitor cells targeting multiple system atrophy-Parkinsonian type, marking its fourth consecutive regulatory approval for CNS cell therapies. This represents clinical validation of allogeneic, off-the-shelf regenerative approaches for a rapidly progressive neurodegenerative disease with no disease-modifying treatments.
Emergency Preparedness in Older Adults With and Without COPD During Power Outages and Natural Disasters
Rural older adults with COPD face disproportionate vulnerability during power outages and natural disasters due to dependence on electrically powered medical devices and limited access to emergency healthcare infrastructure. This population requires targeted preparedness strategies to maintain critical respiratory support and medical continuity during infrastructure failures.
How Are Homebound Older Adults Identified? Definitions, Approaches, and Challenges—A Scoping Review
Homebound status in older adults lacks standardized definitions and identification approaches across healthcare systems, creating fragmentation in care delivery and epidemiological understanding. This definitional inconsistency has direct implications for accurately identifying populations at risk and designing effective interventions that address the underlying factors constraining mobility and social engagement.
Turning your bed into a preventive health platform
Eight Sleep's Pod smart mattress uses continuous biometric monitoring during sleep—tracking heart rate, heart rate variability, and breathing patterns—to shift from reactive treatment to predictive intervention. The company's $1.5 billion valuation reflects a strategic thesis that sleep represents both a high-frequency measurement window and an actionable intervention point for longevity and early disease detection.
Scholar Rock reports 2025 financial results and strategic progress
Scholar Rock reported 2025 revenue of $112.5 million and R&D spending of $278.2 million, with pipeline advancement focused on myostatin-targeting therapeutics for neuromuscular and muscle-related conditions. The company maintains sufficient funding through 2028 to execute clinical development across multiple indications.
Beacon Therapeutics appoints Ryan Robinson as CFO
Beacon Therapeutics appointed Ryan Robinson as CFO to strengthen financial oversight during clinical development. This is a corporate appointment with no direct relevance to longevity research, therapeutics development, or health optimization.
Amylyx Pharmaceuticals narrows losses, advances pivotal avexitide trial
Amylyx Pharmaceuticals reduced net losses by 52% year-over-year while advancing pivotal Phase 3 trials for avexitide in post-bariatric hypoglycemia and expanding its pipeline in rare metabolic and neurologic conditions. The company's cash position supports operations through 2028, positioning it to deliver late-stage clinical data that could establish new treatment options for severe metabolic dysregulation following bariatric surgery.
AEON Clinic rolls out ExoMind for complex mental health conditions
AEON Clinic has launched ExoMind, an integrated treatment program combining clinical assessment, neuromodulation, and psychotherapy for treatment-resistant mental health conditions including OCD, ADHD, and PTSD. The program lacks published clinical trial data or specified regulatory clearances, positioning it as a personalized approach to conditions poorly managed by standard therapies.
Sana Biotechnology reports 2025 financial results and pipeline progress
Sana Biotechnology advanced its engineered cell and gene therapy pipeline while doubling revenue to $138 million and maintaining $1.6 billion in operational funding through 2027. The company is progressing clinical development of candidates for haemoglobinopathies and cancer using ex vivo and in vivo delivery platforms.
ACSS2 maintains oligodendrocyte progenitor cell pool and is required for myelination during development and aging
ACSS2, an enzyme that metabolizes acetate, is required to maintain oligodendrocyte progenitor cells and sustain myelination across the lifespan. Impaired acetate utilization during aging contributes to declining myelin formation, a hallmark of neurological aging.
How to live a long and healthy life, according to the ancients
Ancient Greek and Roman physicians documented longevity patterns through detailed case studies, identifying consistent behavioral practices—meal frequency, diet composition, daily movement, and recovery protocols—that correlated with extended healthspan. These observations predate modern gerontology by nearly two millennia yet align substantively with contemporary longevity research.
Higher tyrosine levels may trim years off life
A UK Biobank study of 272,500 participants links elevated blood tyrosine levels to reduced lifespan, with a stronger effect in men (approximately one year lost per standard deviation increase). Using Mendelian randomization to establish causality rather than mere association, the research suggests tyrosine acts as a causal factor in mortality risk, independent of phenylalanine.
LillyPod is now live to power faster, smarter drug discovery
Eli Lilly's LillyPod supercomputer enables computational modeling of billions of molecular possibilities simultaneously, compressing drug discovery timelines and opening new pathways for interventions targeting age-related diseases. This infrastructure shifts pharmaceutical research from sequential wet-lab testing to parallel computational exploration, with direct implications for accelerating treatments for cardiovascular disease, neurodegeneration, and metabolic dysfunction.
[Editorial] Barriers to accessing cataract surgery
Cataracts affect over half of adults aged 60 and remain the leading cause of blindness globally, despite being correctable through safe, cost-effective surgery. Access disparities mean millions forego vision restoration, a gap that will expand as populations age.
Longevitix named Technology Partner for The Longevity Show 2026
Longevitix, a clinical infrastructure platform, addresses the operational gap between diagnostic data abundance and consistent implementation in longevity medicine. Named Technology Partner for The Longevity Show 2026, the system translates multi-source patient data into structured, evidence-aligned clinical recommendations while automating accountability loops between visits.
Wearable startup Temple secures $54m for brain monitoring
Temple, a wearable startup backed by former Zomato CEO Deepinder Goyal, has raised $54 million to develop a temple-worn device that continuously monitors cerebral blood flow. The device represents a shift in performance monitoring from peripheral metrics like heart rate to direct measurement of brain perfusion during cognitive and physical demands.
Novel Mechanism for Parkinson’s Is Linked to ATP Deficiency
ATP deficiency impairs dopamine packaging into synaptic vesicles by reducing function of VMAT2, a transporter that requires ATP energy, leading to dopamine oxidation and α-synuclein accumulation characteristic of Parkinson's disease. This mechanism links mitochondrial dysfunction to neurodegeneration in human dopaminergic neurons and may explain both familial and sporadic disease pathology.
Nanotech startup lands funding for continuous biosensing platform
Xsensio has secured $7 million in Series A funding to advance a wearable biosensing platform that continuously monitors multiple biomarkers in interstitial fluid, initially targeting early detection of organ dysfunction in acute care settings. Real-time access to biochemical data at the point of care represents a shift from periodic laboratory measurement to continuous physiological surveillance, with potential implications for earlier clinical intervention.
Saving Healthcare Costs in the Real-World: Implementation of CAPABLE in Population-Based Care
Community-based interventions that address functional limitations in older adults reduce hospitalization costs while improving health outcomes. This approach shifts healthcare economics toward prevention and environmental optimization rather than acute care management.
Host Aging Induces a Senescent‐Like Phenotype in Neutrophils and Altered Transcriptional Responses to Streptococcus pneumoniae
Aging drives a senescent-like state in neutrophils characterized by impaired energy metabolism and excessive inflammatory signaling, reducing their capacity to kill respiratory pathogens. Blocking TNFα restores antimicrobial function and improves infection resistance in aged hosts, identifying a tractable mechanism underlying age-related immunocompromise.
A hierarchy of causes of death in senescent C. elegans
Research in senescent C. elegans reveals a hierarchical cascade of organ system failures rather than simultaneous deterioration, with specific tissues failing in sequence as aging progresses. This finding clarifies the mechanistic order of senescent decline and suggests that interventions targeting early failures in this cascade may prevent downstream system collapse.
Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk
The LE8 score—a composite measure of eight cardiovascular and lifestyle factors—independently predicts cancer risk across aging populations. This relationship suggests that modifiable health behaviors affecting circulation, metabolic function, and systemic resilience substantially influence cancer development trajectories.
Advancing senescence translation through the Senotherapeutics Biomarker Consortium
The Senotherapeutics Biomarker Consortium establishes standardized biomarkers for identifying and measuring cellular senescence across tissues and populations, enabling translation of senolytic therapies from research to clinical practice. This addresses a critical gap in longevity medicine: the ability to reliably detect senescent cells and track treatment response in living humans.
Multi-tissue transcriptomic aging atlas reveals predictive aging biomarkers in the killifish
Researchers created a multi-tissue transcriptomic atlas across thirteen tissues in African turquoise killifish at six life stages, identifying molecular patterns of aging that vary by tissue type and sex. This resource establishes predictive biomarkers for aging dynamics and demonstrates how systemic and local factors drive age-related changes across the organism.
Estropausal gut microbiota transplant improves measures of ovarian function in adult mice
Transplanting gut microbiota from aging female mice into young adults restored ovarian hormone profiles, follicle development, and fertility markers, establishing a causal relationship between age-related changes in the microbiome and ovarian function decline. This demonstrates that microbiota composition directly regulates reproductive capacity independent of chronological age.
Can longevity be designed for everyone, not just the wealthy?
Morrow, a Singapore-based longevity clinic, is redesigning accessible healthcare by linking everyday behaviors to measurable health outcomes rather than offering expensive biomarker panels to elites. The model uses lifestyle medicine pillars (diet, activity, stress, sleep, substance avoidance, social connection) paired with AI-assisted monitoring to democratize longevity care for median-income populations.
Juvenescence advances aging drug to Phase 2 trial
Juvenescence's PAI-1 inhibitor MDI-2517 completed Phase 1 trials, demonstrating safety and tolerability for a once-daily oral therapy targeting inflammation and fibrosis—processes central to aging and age-related disease. Genetic evidence suggests PAI-1 reduction correlates with approximately 10 years of extended lifespan, positioning this mechanism as a meaningful target for aging intervention.
Lilly’s orforglipron beats oral semaglutide in diabetes trial
Eli Lilly's orforglipron demonstrated superior blood sugar control (2.2% reduction vs. 1.4%) and weight loss (9.2% vs. 5.3%) compared to oral semaglutide in the ACHIEVE-3 trial of 1,698 adults with type 2 diabetes. The oral formulation's flexibility—taken with meals rather than on an empty stomach—addresses a significant barrier to treatment adherence, though gastrointestinal side effects occurred in approximately 60% of patients.
Youthful blood proteins found in Swiss centenarians
The SWISS100 study reveals that centenarians maintain blood protein profiles resembling those of much younger adults, with notably lower oxidative stress and finely balanced metabolic systems. This molecular signature suggests that exceptional longevity correlates with sustained cellular integrity rather than accelerated compensatory mechanisms, offering a model for understanding how aging can be slowed at the fundamental biological level.
Rejuvenation Roundup February 2026
A February 2026 research roundup covering advances in cellular reprogramming, senolytic effectiveness, immune cell restoration, and cognitive interventions demonstrates multiple convergent pathways for addressing age-related decline. The collective findings suggest that aging is modifiable across multiple biological domains, with implications for clinical translation in vision, neurological, and metabolic disease.
Japanese startup makes hair follicle regeneration breakthrough
OrganTech has identified a three-cell configuration—including a previously uncharacterized mesenchymal cell type—capable of regenerating fully functional hair follicles that maintain cycling and production in vivo. This work establishes a cellular blueprint for hair follicle regeneration and suggests broader applications for complex tissue reconstruction.
#382 ‒ AMA #80: Longevity optimization through strength benchmarks, VO₂ max targets, nutrition principles, brain health, supplements, GLP-1 RAs, wearables, and more
Exercise emerges as the most protective intervention for brain health across the lifespan, with specific performance benchmarks in strength and aerobic capacity serving as measurable proxies for cognitive preservation and longevity. This positions physical capacity as a foundational biomarker that integrates multiple physiological systems rather than a secondary health outcome.
OMICmAge is a multiomic biological aging clock using electronic medical records
Researchers developed OMICmAge, a DNA-methylation-based biological aging clock integrating proteomic and metabolomic data from 31,000 electronic medical records. The measure predicts mortality and age-related disease risk with performance comparable to or superior to existing biomarkers, offering a scalable tool for quantifying biological aging status.
Exercise alleviates cognitive dysfunction in Alzheimer’s disease mice via skeletal muscle-derived extracellular vesicles that enhance plaque clearance by microglia
Swimming exercise in Alzheimer's disease mice triggers release of muscle-derived extracellular vesicles containing miR-378a-3p, which are taken up by microglia to enhance amyloid plaque clearance and attenuate cognitive decline. This identifies a direct mechanistic link between skeletal muscle activity and neuroinflammatory resolution that may inform therapeutic approaches to neurodegenerative disease.